{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:49:15Z","timestamp":1791503355988,"version":"4.3.4"},"reference-count":495,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic reprogramming is a core feature of tumor cells in adapting to microenvironmental stress and acquiring malignant phenotypes. It not only supports rapid proliferation but also mediates immune escape by reshaping the immune microenvironment. In recent years, the \u201cmetabolism-immune axis\u201d, serving as a central hub for the crosstalk between metabolic regulation and immune suppression, has provided a new perspective for understanding tumor immune evasion. This review systematically discusses how metabolic pathways, including glucose, lipid, and amino acid metabolism, along with mitochondrial function and other related processes, shape the immunosuppressive tumor microenvironment by regulating immune cell function, immune checkpoint expression, and immune signaling networks, thereby promoting tumor immune escape. The concept of \u201cmetabolic immune checkpoints (MICs)\u201d is innovatively proposed and classified into three categories based on their mechanisms of action: (1) MIC-I: metabolic modification-type immune checkpoints, exemplified by posttranslational modifications of immune checkpoint molecules such as PD-L1 lactylation, acetylation and glycosylation, etc.; (2) MIC-II: metabolic enzyme-dependent immune regulatory nodes, represented by enzymes such as indoleamine 2,3-dioxygenase 1 and others that directly influence immune cell function; and (3) MIC-III: microbial metabolite-coupled immune regulatory targets, including receptors for microbe-derived metabolites such as short-chain fatty acid receptors. By integrating molecular interaction networks of key targets such as lactate dehydrogenase A and ATP citrate lyase, this review explores synergistic therapeutic strategies that combine small-molecule inhibitors targeting MICs with immune checkpoint blockade. This highlights how metabolic intervention can restore immune cell function and reverse exhaustion. Current key challenges in clinical translation include limitations in metabolic dynamic monitoring technologies, lack of patient stratification biomarkers and insufficient specificity in microbiome regulation. Future directions will focus on personalized treatment guided by multiomics, integrating single-cell metabolic flux analysis, deep learning-driven target prediction, and synthetic microbiome engineering, driving tumor immunotherapy into the era of precision metabolic regulation. By integrating the fundamental mechanisms of MICs with translational medical research, this review not only provides a systematic paradigm but also establishes a foundation for the development of new-generation precision combination therapies.<\/jats:p>","DOI":"10.1038\/s41392-026-02903-1","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:01:45Z","timestamp":1791500505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation"],"prefix":"10.1038","volume":"11","author":[{"given":"Jinru","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0863-594X","authenticated-orcid":false,"given":"Xing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-9864","authenticated-orcid":false,"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2903_CR1","doi-asserted-by":"publisher","first-page":"216396","DOI":"10.1016\/j.canlet.2023.216396","volume":"575","author":"Z Luo","year":"2023","unstructured":"Luo, Z., Eichinger, K. M., Zhang, A. & Li, S. Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Lett 575, 216396 (2023).","journal-title":"Cancer Lett"},{"key":"2903_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B. et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target Ther 9, 274 (2024).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02205-6","volume":"24","author":"K Huang","year":"2025","unstructured":"Huang, K. et al. Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy. Mol. Cancer 24, 7 (2025).","journal-title":"Mol. Cancer"},{"key":"2903_CR4","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","volume":"187","author":"SM Fendt","year":"2024","unstructured":"Fendt, S. M. 100 years of the Warburg effect: a cancer metabolism endeavor. Cell 187, 3824\u20133828 (2024).","journal-title":"Cell"},{"key":"2903_CR5","doi-asserted-by":"publisher","first-page":"e09989","DOI":"10.1002\/advs.202509989","volume":"12","author":"H Shen","year":"2025","unstructured":"Shen, H. et al. Lactate metabolic reprogramming mediated by CircRNA-LDHA complex facilitates innate immune evasion of liver cancer. Adv. Sci. 12, e09989 (2025).","journal-title":"Adv. Sci."},{"key":"2903_CR6","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1007\/s11427-025-2979-3","volume":"68","author":"S Lyu","year":"2025","unstructured":"Lyu, S., Gildor, N., Zhang, Q. & Liao, C. Rewiring cancer metabolism: oncogenic signaling pathways and targeted therapeutics. Sci. China Life Sci 68, 3281\u20133302 (2025).","journal-title":"Sci. China Life Sci"},{"key":"2903_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","volume":"17","author":"J Lin","year":"2024","unstructured":"Lin, J., Rao, D., Zhang, M. & Gao, Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J. Hematol. Oncol. 17, 6 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2903_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42255-023-00963-z","volume":"6","author":"M Demicco","year":"2024","unstructured":"Demicco, M., Liu, X. Z., Leithner, K. & Fendt, S. M. Metabolic heterogeneity in cancer. Nat. Metab. 6, 18\u201338 (2024).","journal-title":"Nat. Metab."},{"key":"2903_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","volume":"44","author":"Y Liu","year":"2026","unstructured":"Liu, Y., Dai, Y. & Wang, L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell 44, 24\u201349 (2026).","journal-title":"Cancer Cell"},{"key":"2903_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38360-5","volume":"14","author":"C Sun","year":"2023","unstructured":"Sun, C. et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat. Commun. 14, 2692 (2023).","journal-title":"Nat. Commun."},{"key":"2903_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421\u2013433 (2023).","journal-title":"Cancer Cell"},{"key":"2903_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","volume":"25","author":"P Altea-Manzano","year":"2025","unstructured":"Altea-Manzano, P., Decker-Farrell, A., Janowitz, T. & Erez, A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. Nat. Rev. Cancer 25, 274\u2013292 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ccell.2025.04.004","volume":"43","author":"I Vogel","year":"2025","unstructured":"Vogel, I. & Bapat, S. P. TAMing immunity through an unexpected source. Cancer Cell 43, 1002\u20131004 (2025).","journal-title":"Cancer Cell"},{"key":"2903_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s43018-023-00671-3","volume":"5","author":"F Li","year":"2024","unstructured":"Li, F. et al. Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. Nat. Cancer 5, 131\u2013146 (2024).","journal-title":"Nat. Cancer"},{"key":"2903_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/ajrccm\/aamag150","volume":"212","author":"F Meng","year":"2026","unstructured":"Meng, F. et al. Hypoxic niche drives lineage imbalance and early tumorigenesis in EGFR-mutant lung cancer. Am. J. Respir. Crit. Care Med. 212, 1140\u20131155 (2026).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2903_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s42255-025-01287-w","volume":"7","author":"A Nobels","year":"2025","unstructured":"Nobels, A. et al. The gut microbiome and cancer: from tumorigenesis to therapy. Nat. Metab. 7, 895\u2013917 (2025).","journal-title":"Nat. Metab."},{"key":"2903_CR17","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong, H. et al. Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab 36, 2493\u20132510.e2499 (2024).","journal-title":"Cell Metab"},{"key":"2903_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","volume":"39","author":"JE Cheong","year":"2018","unstructured":"Cheong, J. E. & Sun, L. Targeting the IDO1\/TDO2-KYN-AhR pathway for cancer immunotherapy\u2014challenges and opportunities. Trends Pharm. Sci. 39, 307\u2013325 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"2903_CR19","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/nu14091977","volume":"14","author":"J Cong","year":"2022","unstructured":"Cong, J., Zhou, P. & Zhang, R. Intestinal microbiota-derived short chain fatty acids in host health and disease. Nutrients. 14, 1977 (2022).","journal-title":"Nutrients."},{"key":"2903_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59878-w","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Dynamic single-cell metabolomics reveals cell-cell interaction between tumor cells and macrophages. Nat. Commun. 16, 4582 (2025).","journal-title":"Nat. Commun."},{"key":"2903_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","volume":"598","author":"FP Canale","year":"2021","unstructured":"Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662\u2013666 (2021).","journal-title":"Nature"},{"key":"2903_CR22","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.34133\/research.1070","volume":"9","author":"S Wei","year":"2026","unstructured":"Wei, S. et al. A novel autophagy inhibitor p-hydroxylcinnamaldehyde suppresses esophageal squamous cell carcinoma by targeting ldha phosphorylation-mediated metabolic reprogramming. Research 9, 1070 (2026).","journal-title":"Research"},{"key":"2903_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-025-09297-0","volume":"645","author":"J Gautam","year":"2025","unstructured":"Gautam, J. et al. ACLY inhibition promotes tumour immunity and suppresses liver cancer. Nature 645, 507\u2013517 (2025).","journal-title":"Nature"},{"key":"2903_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.cmet.2026.01.015","volume":"38","author":"S Chen","year":"2026","unstructured":"Chen, S. et al. 16-h fasting optimizes cancer immunotherapy in mice and humans. Cell Metab 38, 944\u2013962.e914 (2026).","journal-title":"Cell Metab"},{"key":"2903_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg, K. C., de Groot, A. E. & Pienta, K. J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15, 366\u2013381 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2903_CR26","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharm. Ther. 221, 107753 (2021).","journal-title":"Pharm. Ther."},{"key":"2903_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: still emerging. Cell Metab 34, 355\u2013377 (2022).","journal-title":"Cell Metab"},{"key":"2903_CR28","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science. 368, eaaw5473 (2020).","journal-title":"Science."},{"key":"2903_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino, M., Rathmell, J. C., Galluzzi, L. & Vanpouille-Box, C. Cancer cell metabolism and antitumour immunity. Nat. Rev. Immunol. 24, 654\u2013669 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol. Cancer 23, 203 (2024).","journal-title":"Mol. Cancer"},{"key":"2903_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56392-x","volume":"16","author":"C Niveau","year":"2025","unstructured":"Niveau, C. et al. MCT1 lactate transporter blockade re-invigorates anti-tumor immunity through metabolic rewiring of dendritic cells in melanoma. Nat. Commun. 16, 1083 (2025).","journal-title":"Nat. Commun."},{"key":"2903_CR32","doi-asserted-by":"publisher","first-page":"e202451102","DOI":"10.1002\/eji.202451102","volume":"55","author":"F Gao","year":"2025","unstructured":"Gao, F., Shah, R., Xin, G. & Wang, R. Metabolic dialogue shapes immune response in the tumor microenvironment. Eur. J. Immunol. 55, e202451102 (2025).","journal-title":"Eur. J. Immunol."},{"key":"2903_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619\u2013634 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325\u2013337 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard, P. et al. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist. Updat. 38, 1\u201311 (2018).","journal-title":"Drug Resist. Updat."},{"key":"2903_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jcsm.12654","volume":"12","author":"H Mollazadeh","year":"2021","unstructured":"Mollazadeh, H. et al. Effects of statins on mitochondrial pathways. J. Cachexia Sarcopenia Muscle 12, 237\u2013251 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2903_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0667-y","volume":"16","author":"G Cesi","year":"2017","unstructured":"Cesi, G. et al. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol. Cancer 16, 102 (2017).","journal-title":"Mol. Cancer"},{"key":"2903_CR38","doi-asserted-by":"publisher","first-page":"589601","DOI":"10.3389\/fonc.2020.589601","volume":"10","author":"A Martincuks","year":"2020","unstructured":"Martincuks, A. et al. CD44 in ovarian cancer progression and therapy resistance-a critical role for STAT3. Front Oncol 10, 589601 (2020).","journal-title":"Front Oncol"},{"key":"2903_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1034-7","volume":"20","author":"RS da Cruz","year":"2018","unstructured":"da Cruz, R. S. et al. Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring. Breast Cancer Res 20, 99 (2018).","journal-title":"Breast Cancer Res"},{"key":"2903_CR40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cac2.12187","volume":"41","author":"L He","year":"2021","unstructured":"He, L. et al. Squalene epoxidase promotes colorectal cancer cell proliferation through accumulating calcitriol and activating CYP24A1-mediated MAPK signaling. Cancer Commun 41, 726\u2013746 (2021).","journal-title":"Cancer Commun"},{"key":"2903_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/antiox12030771","volume":"12","author":"K Rubio","year":"2023","unstructured":"Rubio, K. et al. Nutriepigenomics in environmental-associated oxidative stress. Antioxidants 12, 771 (2023).","journal-title":"Antioxidants"},{"key":"2903_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"2903_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2903_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov 12, 31\u201346 (2022).","journal-title":"Cancer Discov"},{"key":"2903_CR45","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","volume":"10","author":"ZJ Yang","year":"2011","unstructured":"Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 10, 1533\u20131541 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"2903_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/0008-5472.CAN-24-2324","volume":"85","author":"YW Luo","year":"2025","unstructured":"Luo, Y. W. et al. HIF1\u03b1 counteracts TGF\u03b21-driven TSP1 expression in endothelial cells to stimulate angiogenesis in the hypoxic tumor microenvironment. Cancer Res 85, 69\u201383 (2025).","journal-title":"Cancer Res"},{"key":"2903_CR47","doi-asserted-by":"publisher","first-page":"1597770","DOI":"10.3389\/fimmu.2025.1597770","volume":"16","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. Targeting metabolic reprogramming to overcome immune tolerance in melanoma immunotherapy. Front. Immunol. 16, 1597770 (2025).","journal-title":"Front. Immunol."},{"key":"2903_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/2159-8290.CD-21-0922","volume":"12","author":"R Pillai","year":"2022","unstructured":"Pillai, R., Hayashi, M., Zavitsanou, A. M. & Papagiannakopoulos, T. NRF2: KEAPing tumors protected. Cancer Discov 12, 625\u2013643 (2022).","journal-title":"Cancer Discov"},{"key":"2903_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fimmu.2015.00099","volume":"6","author":"G Ramsay","year":"2015","unstructured":"Ramsay, G. & Cantrell, D. Environmental and metabolic sensors that control T cell biology. Front. Immunol. 6, 99 (2015).","journal-title":"Front. Immunol."},{"key":"2903_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-024-01865-z","volume":"10","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov 10, 118 (2024).","journal-title":"Cell Death Discov"},{"key":"2903_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-017-0172-1","volume":"5","author":"AN Lau","year":"2017","unstructured":"Lau, A. N. et al. PKM2 is not required for colon cancer initiated by APC loss. Cancer Metab 5, 10 (2017).","journal-title":"Cancer Metab"},{"key":"2903_CR52","doi-asserted-by":"publisher","first-page":"e14797","DOI":"10.7717\/peerj.14797","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Multifaceted roles of aerobic glycolysis and oxidative phosphorylation in hepatocellular carcinoma. PeerJ 11, e14797 (2023).","journal-title":"PeerJ"},{"key":"2903_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s43556-024-00229-4","volume":"5","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Tumor energy metabolism: implications for therapeutic targets. Mol. Biomed. 5, 63 (2024).","journal-title":"Mol. Biomed."},{"key":"2903_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri, E. & Santoro, M. M. ROS homeostasis and metabolism: a dangerous liaison in cancer cells. Cell Death Dis 7, e2253 (2016).","journal-title":"Cell Death Dis"},{"key":"2903_CR55","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.semcancer.2015.10.002","volume":"35","author":"MD Hirschey","year":"2015","unstructured":"Hirschey, M. D. et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol 35, S129\u2013S150 (2015).","journal-title":"Semin Cancer Biol"},{"key":"2903_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0623-9","volume":"9","author":"J Wei","year":"2018","unstructured":"Wei, J. et al. Salvianolic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K\/AKT\/HIF-1\u03b1 signaling pathway. Cell Death Dis 9, 599 (2018).","journal-title":"Cell Death Dis"},{"key":"2903_CR57","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.immuni.2021.04.008","volume":"54","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. Immunity 54, 976\u2013987.e977 (2021).","journal-title":"Immunity"},{"key":"2903_CR58","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s12672-025-02782-y","volume":"16","author":"M Yuan","year":"2025","unstructured":"Yuan, M. et al. Lactate metabolism-related genes serve as potential biomarkers for predicting gastric cancer progression and immunotherapy. Discov. Oncol. 16, 1012 (2025).","journal-title":"Discov. Oncol."},{"key":"2903_CR59","doi-asserted-by":"publisher","first-page":"loaf008","DOI":"10.1093\/lifemeta\/loaf008","volume":"4","author":"Y Yuan","year":"2025","unstructured":"Yuan, Y. & Chen, L. Transporters in vitamin uptake and cellular metabolism: impacts on health and disease. Life Metab. 4, loaf008 (2025).","journal-title":"Life Metab."},{"key":"2903_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.587","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4. Cell Death Dis 6, e1620 (2015).","journal-title":"Cell Death Dis"},{"key":"2903_CR61","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jid.2019.12.011","volume":"140","author":"F Wang","year":"2020","unstructured":"Wang, F., Yang, T. B. & Kim, B. S. The return of the mast cell: new roles in neuroimmune itch biology. J. Investig. Dermatol. 140, 945\u2013951 (2020).","journal-title":"J. Investig. Dermatol."},{"key":"2903_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02258-1","volume":"24","author":"M Wan","year":"2025","unstructured":"Wan, M. et al. Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment. Mol. Cancer 24, 61 (2025).","journal-title":"Mol. Cancer"},{"key":"2903_CR63","first-page":"597","volume":"22","author":"D Bandyopadhyay","year":"2024","unstructured":"Bandyopadhyay, D. et al. Momordicine-I suppresses head and neck cancer growth by modulating key metabolic pathways. Cell Commun. Signal 22, 597 (2024).","journal-title":"Signal"},{"key":"2903_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12672-023-00830-z","volume":"14","author":"X You","year":"2023","unstructured":"You, X. et al. A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer. Discov. Oncol. 14, 207 (2023).","journal-title":"Discov. Oncol."},{"key":"2903_CR65","doi-asserted-by":"publisher","first-page":"2024051","DOI":"10.1080\/23723556.2021.2024051","volume":"9","author":"D Capece","year":"2022","unstructured":"Capece, D. & Franzoso, G. Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma. Mol. Cell Oncol. 9, 2024051 (2022).","journal-title":"Mol. Cell Oncol."},{"key":"2903_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","volume":"31","author":"MT Snaebjornsson","year":"2020","unstructured":"Snaebjornsson, M. T., Janaki-Raman, S. & Schulze, A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab 31, 62\u201376 (2020).","journal-title":"Cell Metab"},{"key":"2903_CR67","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1042\/BCJ20190468","volume":"477","author":"A Yang","year":"2020","unstructured":"Yang, A. & Mottillo, E. P. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochem. J. 477, 985\u20131008 (2020).","journal-title":"Biochem. J."},{"key":"2903_CR68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1365-2567.2006.02376.x","volume":"118","author":"M Okano","year":"2006","unstructured":"Okano, M. et al. E prostanoid 2 (EP2)\/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology 118, 343\u2013352 (2006).","journal-title":"Immunology"},{"key":"2903_CR69","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/antiox14060735","volume":"14","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Oxidative stress and inflammation: drivers of tumorigenesis and therapeutic opportunities. Antioxidants 14, 735 (2025).","journal-title":"Antioxidants"},{"key":"2903_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28417-2","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu, S. et al. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. Nat. Commun. 13, 731 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR71","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1002\/cam4.4699","volume":"11","author":"M Kurano","year":"2022","unstructured":"Kurano, M., Sakai, E. & Yatomi, Y. Understanding modulations of lipid mediators in cancer using a murine model of carcinomatous peritonitis. Cancer Med 11, 3491\u20133507 (2022).","journal-title":"Cancer Med"},{"key":"2903_CR72","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/0008-5472.CAN-23-0104","volume":"84","author":"S Pietrobono","year":"2024","unstructured":"Pietrobono, S. et al. Autotaxin secretion is a stromal mechanism of adaptive resistance to TGF\u03b2 inhibition in pancreatic ductal adenocarcinoma. Cancer Res 84, 118\u2013132 (2024).","journal-title":"Cancer Res"},{"key":"2903_CR73","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.3390\/ijms14047742","volume":"14","author":"CE Pyragius","year":"2013","unstructured":"Pyragius, C. E., Fuller, M., Ricciardelli, C. & Oehler, M. K. Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int. J. Mol. Sci. 14, 7742\u20137756 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cellsig.2008.10.010","volume":"21","author":"Y Zhao","year":"2009","unstructured":"Zhao, Y. & Natarajan, V. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell Signal 21, 367\u2013377 (2009).","journal-title":"Cell Signal"},{"key":"2903_CR75","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4161\/cc.8.22.9937","volume":"8","author":"S Liu","year":"2009","unstructured":"Liu, S., Murph, M., Panupinthu, N. & Mills, G. B. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8, 3695\u20133701 (2009).","journal-title":"Cell Cycle"},{"key":"2903_CR76","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.molcel.2024.04.012","volume":"84","author":"C Yang","year":"2024","unstructured":"Yang, C. et al. Arginine deprivation enriches lung cancer proteomes with cysteine by inducing arginine-to-cysteine substitutants. Mol. Cell 84, 1904\u20131916.e1907 (2024).","journal-title":"Mol. Cell"},{"key":"2903_CR77","first-page":"45","volume":"23","author":"D Nan","year":"2025","unstructured":"Nan, D. et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets. Cell Commun. Signal 23, 45 (2025).","journal-title":"Signal"},{"key":"2903_CR78","doi-asserted-by":"publisher","first-page":"mjad007","DOI":"10.1093\/jmcb\/mjad007","volume":"15","author":"W Dai","year":"2023","unstructured":"Dai, W. & Zong, W. X. Glutamine synthetase: a tumor suppressor in hepatocellular carcinoma? J. Mol. Cell Biol. 15, mjad007 (2023).","journal-title":"J. Mol. Cell Biol."},{"key":"2903_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05409-0","volume":"13","author":"X Yin","year":"2022","unstructured":"Yin, X. et al. Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis. Cell Death Dis 13, 955 (2022).","journal-title":"Cell Death Dis"},{"key":"2903_CR80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","volume":"6","author":"LE Navas","year":"2021","unstructured":"Navas, L. E. & Carnero, A. NAD(+) metabolism, stemness, the immune response, and cancer. Signal Transduct. Target. Ther. 6, 2 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2903_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07868-6","volume":"9","author":"MA Reid","year":"2018","unstructured":"Reid, M. A. et al. Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism. Nat. Commun. 9, 5442 (2018).","journal-title":"Nat. Commun."},{"key":"2903_CR82","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1038\/s41388-019-0967-3","volume":"38","author":"A Alptekin","year":"2019","unstructured":"Alptekin, A. et al. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity. Oncogene 38, 7504\u20137520 (2019).","journal-title":"Oncogene"},{"key":"2903_CR83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13072-025-00575-9","volume":"18","author":"K Zhang","year":"2025","unstructured":"Zhang, K. & Jagannath, C. Crosstalk between metabolism and epigenetics during macrophage polarization. Epigenet. Chromatin 18, 16 (2025).","journal-title":"Epigenet. Chromatin"},{"key":"2903_CR84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.devcel.2020.06.018","volume":"54","author":"F Li","year":"2020","unstructured":"Li, F. & Simon, M. C. Cancer cells don\u2019t live alone: metabolic communication within tumor microenvironments. Dev. Cell 54, 183\u2013195 (2020).","journal-title":"Dev. Cell"},{"key":"2903_CR85","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","volume":"55","author":"SK Seo","year":"2023","unstructured":"Seo, S. K. & Kwon, B. Immune regulation through tryptophan metabolism. Exp. Mol. Med. 55, 1371\u20131379 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2903_CR86","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ni.3415","volume":"17","author":"CH Chang","year":"2016","unstructured":"Chang, C. H. & Pearce, E. L. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17, 364\u2013368 (2016).","journal-title":"Nat. Immunol."},{"key":"2903_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","volume":"52","author":"EL Lieu","year":"2020","unstructured":"Lieu, E. L., Nguyen, T., Rhyne, S. & Kim, J. Amino acids in cancer. Exp. Mol. Med. 52, 15\u201330 (2020).","journal-title":"Exp. Mol. Med."},{"key":"2903_CR88","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/ijms27041650","volume":"27","author":"N Or\u0161oli\u0107","year":"2026","unstructured":"Or\u0161oli\u0107, N., Ku\u010dan, D. & Jazvin\u0161\u0107ak Jembrek, M. Enhancing cancer therapy with hyperthermia: synergistic effects with natural compounds and conventional treatments. Int. J. Mol. Sci. 27, 1650 (2026).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du, H. et al. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct. Target Ther 10, 245 (2025).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR90","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.3390\/ijms21093363","volume":"21","author":"P Ghosh","year":"2020","unstructured":"Ghosh, P., Vidal, C., Dey, S. & Zhang, L. Mitochondria targeting as an effective strategy for cancer therapy. Int. J. Mol. Sci. 21, 3363 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR91","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.ccell.2022.10.004","volume":"40","author":"H Weng","year":"2022","unstructured":"Weng, H. et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell 40, 1566\u20131582.e1510 (2022).","journal-title":"Cancer Cell"},{"key":"2903_CR92","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/j.clgc.2016.11.010","volume":"15","author":"J Ellinger","year":"2017","unstructured":"Ellinger, J. et al. Systematic expression analysis of mitochondrial complex I identifies NDUFS1 as a biomarker in clear-cell renal-cell carcinoma. Clin. Genitourin. Cancer 15, e551\u2013e562 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"2903_CR93","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12951-021-01053-6","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang, X., Hu, C., Gu, Z. & Dai, L. Understanding of catalytic ROS generation from defect-rich graphene quantum-dots for therapeutic effects in tumor microenvironment. J. Nanobiotechnol. 19, 340 (2021).","journal-title":"J. Nanobiotechnol."},{"key":"2903_CR94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-025-00505-5","volume":"14","author":"W Li","year":"2025","unstructured":"Li, W. et al. Molecular mechanisms of mitochondrial quality control. Transl. Neurodegener. 14, 45 (2025).","journal-title":"Transl. Neurodegener."},{"key":"2903_CR95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/metabo15040277","volume":"15","author":"M Ghanbarian","year":"2025","unstructured":"Ghanbarian, M. et al. Metabolic effects of the cancer metastasis modulator MEMO1. Metabolites. 15, 277 (2025).","journal-title":"Metabolites."},{"key":"2903_CR96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2015.05.003","volume":"152","author":"SJ Parker","year":"2015","unstructured":"Parker, S. J. & Metallo, C. M. Metabolic consequences of oncogenic IDH mutations. Pharm. Ther. 152, 54\u201362 (2015).","journal-title":"Pharm. Ther."},{"key":"2903_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai, E. et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol. Cancer 20, 171 (2021).","journal-title":"Mol. Cancer"},{"key":"2903_CR98","doi-asserted-by":"publisher","first-page":"eabf9441","DOI":"10.1126\/sciadv.abf9441","volume":"7","author":"JW Luzwick","year":"2021","unstructured":"Luzwick, J. W. et al. MRE11-dependent instability in mitochondrial DNA fork protection activates a cGAS immune signaling pathway. Sci. Adv. 7, eabf9441 (2021).","journal-title":"Sci. Adv."},{"key":"2903_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04934-0","volume":"22","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Wnt\/\u03b2-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer. J. Transl. Med. 22, 133 (2024).","journal-title":"J. Transl. Med."},{"key":"2903_CR100","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger, K. et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 372, 156\u2013165 (2021).","journal-title":"Science"},{"key":"2903_CR101","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cmet.2013.11.004","volume":"18","author":"J Ding","year":"2013","unstructured":"Ding, J. et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab 18, 896\u2013907 (2013).","journal-title":"Cell Metab"},{"key":"2903_CR102","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1016\/j.cell.2024.05.011","volume":"187","author":"DH Tran","year":"2024","unstructured":"Tran, D. H. et al. De novo and salvage purine synthesis pathways across tissues and tumors. Cell 187, 3602\u20133618.e3620 (2024).","journal-title":"Cell"},{"key":"2903_CR103","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1016\/j.gendis.2022.04.018","volume":"10","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. De novo nucleotide biosynthetic pathway and cancer. Genes Dis 10, 2331\u20132338 (2023).","journal-title":"Genes Dis"},{"key":"2903_CR104","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1158\/2767-9764.CRC-22-0256","volume":"2","author":"NE Cortez","year":"2022","unstructured":"Cortez, N. E. et al. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice. Cancer Res. Commun. 2, 951\u2013965 (2022).","journal-title":"Cancer Res. Commun."},{"key":"2903_CR105","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1743-7075-8-54","volume":"8","author":"M Schmidt","year":"2011","unstructured":"Schmidt, M. et al. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr. Metab. 8, 54 (2011).","journal-title":"Nutr. Metab."},{"key":"2903_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07390-6","volume":"23","author":"L Du","year":"2025","unstructured":"Du, L. & Yang, H. Spatial omics in 3D culture model systems: decoding cellular positioning mechanisms and microenvironmental dynamics. J. Transl. Med. 23, 1356 (2025).","journal-title":"J. Transl. Med."},{"key":"2903_CR107","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/adhm.201500441","volume":"4","author":"R Agarwal","year":"2015","unstructured":"Agarwal, R. et al. Effect of shape, size, and aspect ratio on nanoparticle penetration and distribution inside solid tissues using 3D spheroid models. Adv. Health. Mater. 4, 2269\u20132280 (2015).","journal-title":"Adv. Health. Mater."},{"key":"2903_CR108","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","volume":"82","author":"E Boedtkjer","year":"2020","unstructured":"Boedtkjer, E. & Pedersen, S. F. The acidic tumor microenvironment as a driver of cancer. Annu. Rev. Physiol. 82, 103\u2013126 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"2903_CR109","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Y Feng","year":"2024","unstructured":"Feng, Y. et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J. Nanobiotechnol. 22, 737 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2903_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10020-025-01205-6","volume":"31","author":"W Zhang","year":"2025","unstructured":"Zhang, W. et al. Warburg effect and lactylation in cancer: mechanisms for chemoresistance. Mol. Med. 31, 146 (2025).","journal-title":"Mol. Med."},{"key":"2903_CR111","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy, A., Bai, Z., Satija, R. & Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 24, 695\u2013713 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2903_CR112","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41577-024-01084-8","volume":"24","author":"M Allam","year":"2024","unstructured":"Allam, M. & Coskun, A. F. Combining spatial metabolomics and proteomics profiling of single cells. Nat. Rev. Immunol. 24, 701 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR113","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","volume":"24","author":"K Vandereyken","year":"2023","unstructured":"Vandereyken, K., Sifrim, A., Thienpont, B. & Voet, T. Methods and applications for single-cell and spatial multi-omics. Nat. Rev. Genet. 24, 494\u2013515 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"2903_CR114","doi-asserted-by":"publisher","first-page":"1243259","DOI":"10.1126\/science.1243259","volume":"342","author":"R Zenobi","year":"2013","unstructured":"Zenobi, R. Single-cell metabolomics: analytical and biological perspectives. Science 342, 1243259 (2013).","journal-title":"Science"},{"key":"2903_CR115","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41592-021-01333-x","volume":"18","author":"C Seydel","year":"2021","unstructured":"Seydel, C. Single-cell metabolomics hits its stride. Nat. Methods 18, 1452\u20131456 (2021).","journal-title":"Nat. Methods"},{"key":"2903_CR116","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3390\/ijms25031628","volume":"25","author":"AN Neagu","year":"2024","unstructured":"Neagu, A. N. et al. Onco-breastomics: an eco-evo-devo holistic approach. Int. J. Mol. Sci. 25, 1628 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR117","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1111\/cas.70138","volume":"116","author":"Z Dai","year":"2025","unstructured":"Dai, Z. et al. Heterogeneity in osteosarcoma revealed by scRNA sequencing: CLU+ endothelial cells as key players in tumor progression. Cancer Sci 116, 2568\u20132579 (2025).","journal-title":"Cancer Sci"},{"key":"2903_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05606-9","volume":"22","author":"X Cai","year":"2024","unstructured":"Cai, X. et al. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis. J. Transl. Med. 22, 807 (2024).","journal-title":"J. Transl. Med."},{"key":"2903_CR119","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/ijms26020669","volume":"26","author":"Y Vijayanathan","year":"2025","unstructured":"Vijayanathan, Y. & Ho, I. A. W. The impact of metabolic rewiring in glioblastoma: the immune landscape and therapeutic strategies. Int. J. Mol. Sci. 26, 669 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR120","doi-asserted-by":"publisher","first-page":"1022716","DOI":"10.3389\/fonc.2022.1022716","volume":"12","author":"A Silver","year":"2022","unstructured":"Silver, A. et al. Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization. Front. Oncol. 12, 1022716 (2022).","journal-title":"Front. Oncol."},{"key":"2903_CR121","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41592-024-02392-6","volume":"21","author":"JB Nunes","year":"2024","unstructured":"Nunes, J. B. et al. Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling. Nat. Methods 21, 1796\u20131800 (2024).","journal-title":"Nat. Methods"},{"key":"2903_CR122","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell 40, 639\u2013655.e613 (2022).","journal-title":"Cancer Cell"},{"key":"2903_CR123","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1021\/acschemneuro.4c00463","volume":"16","author":"TFE Hendriks","year":"2025","unstructured":"Hendriks, T. F. E. et al. Integrating rapid evaporative ionization mass spectrometry classification with matrix-assisted laser desorption ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry to unveil glioblastoma overall survival prediction. ACS Chem. Neurosci. 16, 1021\u20131033 (2025).","journal-title":"ACS Chem. Neurosci."},{"key":"2903_CR124","doi-asserted-by":"publisher","first-page":"eadi2465","DOI":"10.1126\/sciadv.adi2465","volume":"9","author":"W Xiang","year":"2023","unstructured":"Xiang, W. et al. Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. Sci. Adv. 9, eadi2465 (2023).","journal-title":"Sci. Adv."},{"key":"2903_CR125","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.immuni.2024.03.021","volume":"57","author":"J Xiao","year":"2024","unstructured":"Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity 57, 1087\u20131104.e1087 (2024).","journal-title":"Immunity"},{"key":"2903_CR126","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jare.2025.01.021","volume":"77","author":"Y Cui","year":"2025","unstructured":"Cui, Y. et al. Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment. J. Adv. Res. 77, 721\u2013732 (2025).","journal-title":"J. Adv. Res."},{"key":"2903_CR127","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cpt.2024.09.006","volume":"3","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8(+) T cell anti-tumor immunity. Cancer Pathog. Ther. 3, 253\u2013266 (2025).","journal-title":"Cancer Pathog. Ther."},{"key":"2903_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi, D. et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat. Commun. 13, 5644 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR129","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Lactate and lactylation in cancer. Signal Transduct. Target Ther 10, 38 (2025).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02407-6","volume":"24","author":"Y Lv","year":"2025","unstructured":"Lv, Y. et al. Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy. Mol. Cancer 24, 210 (2025).","journal-title":"Mol. Cancer"},{"key":"2903_CR131","doi-asserted-by":"publisher","first-page":"e70044","DOI":"10.1002\/cai2.70044","volume":"5","author":"X Cai","year":"2026","unstructured":"Cai, X. et al. An anoikis resistance phenotype converged to immune dysfunction and resistance to immune checkpoint blockades in gastric cancer. Cancer Innov 5, e70044 (2026).","journal-title":"Cancer Innov"},{"key":"2903_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00917-0","volume":"12","author":"X Cai","year":"2026","unstructured":"Cai, X. et al. The landscape of B and plasma cells in breast cancer: insights from single-cell and spatial transcriptomics. NPJ Breast Cancer 12, 61 (2026).","journal-title":"NPJ Breast Cancer"},{"key":"2903_CR133","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nri.2017.99","volume":"18","author":"GR Bantug","year":"2018","unstructured":"Bantug, G. R., Galluzzi, L., Kroemer, G. & Hess, C. The spectrum of T cell metabolism in health and disease. Nat. Rev. Immunol. 18, 19\u201334 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR134","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","volume":"25","author":"D Hanahan","year":"2025","unstructured":"Hanahan, D., Michielin, O. & Pittet, M. J. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat. Rev. Cancer 25, 41\u201358 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR135","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","volume":"24","author":"PDA Vignali","year":"2023","unstructured":"Vignali, P. D. A. et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat. Immunol. 24, 267\u2013279 (2023).","journal-title":"Nat. Immunol."},{"key":"2903_CR136","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaci.2022.10.011","volume":"151","author":"L Chopp","year":"2023","unstructured":"Chopp, L., Redmond, C., O\u2019Shea, J. J. & Schwartz, D. M. From thymus to tissues and tumors: A review of T-cell biology. J. Allergy Clin. Immunol. 151, 81\u201397 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2903_CR137","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ijc.33781","volume":"150","author":"Y Li","year":"2022","unstructured":"Li, Y., Tang, J., Jiang, J. & Chen, Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int. J. Cancer 150, 195\u2013207 (2022).","journal-title":"Int. J. Cancer"},{"key":"2903_CR138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10238-024-01429-6","volume":"24","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Immunometabolic alteration of CD4(+) T cells in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Clin. Exp. Med. 24, 163 (2024).","journal-title":"Clin. Exp. Med."},{"key":"2903_CR139","doi-asserted-by":"publisher","first-page":"112996","DOI":"10.1016\/j.celrep.2023.112996","volume":"42","author":"H Sun","year":"2023","unstructured":"Sun, H. et al. IL-2 can signal via chemokine receptors to promote regulatory T cells\u2019 suppressive function. Cell Rep 42, 112996 (2023).","journal-title":"Cell Rep"},{"key":"2903_CR140","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12929-023-00956-w","volume":"30","author":"SF Wang","year":"2023","unstructured":"Wang, S. F., Tseng, L. M. & Lee, H. C. Role of mitochondrial alterations in human cancer progression and cancer immunity. J. Biomed. Sci. 30, 61 (2023).","journal-title":"J. Biomed. Sci."},{"key":"2903_CR141","first-page":"7","volume":"8","author":"C Suri","year":"2025","unstructured":"Suri, C. et al. Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance. Cancer Drug Resist 8, 7 (2025).","journal-title":"Cancer Drug Resist"},{"key":"2903_CR142","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00018-022-04582-x","volume":"79","author":"E Zhang","year":"2022","unstructured":"Zhang, E., Ma, Z. & Lu, M. Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases. Cell Mol. Life Sci 79, 547 (2022).","journal-title":"Cell Mol. Life Sci"},{"key":"2903_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00438-y","volume":"11","author":"J Park","year":"2022","unstructured":"Park, J., Wang, L. & Ho, P. C. Metabolic guidance and stress in tumors modulate antigen-presenting cells. Oncogenesis 11, 62 (2022).","journal-title":"Oncogenesis"},{"key":"2903_CR144","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","volume":"197","author":"PJ Siska","year":"2016","unstructured":"Siska, P. J. et al. Suppression of Glut1 and glucose metabolism by decreased Akt\/mTORC1 signaling drives T cell impairment in B cell leukemia. J. Immunol. 197, 2532\u20132540 (2016).","journal-title":"J. Immunol."},{"key":"2903_CR145","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1007\/s12035-025-04775-y","volume":"62","author":"M Fang","year":"2025","unstructured":"Fang, M. et al. Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative Diseases and Targeted Therapy. Mol. Neurobiol. 62, 8204\u20138221 (2025).","journal-title":"Mol. Neurobiol."},{"key":"2903_CR146","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1016\/j.immuni.2022.10.020","volume":"55","author":"S Lukhele","year":"2022","unstructured":"Lukhele, S. et al. The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunity. Immunity 55, 2369\u20132385.e2310 (2022).","journal-title":"Immunity"},{"key":"2903_CR147","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41420-024-02011-5","volume":"10","author":"N Wang","year":"2024","unstructured":"Wang, N. et al. AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment? Cell Death Discov 10, 237 (2024).","journal-title":"Cell Death Discov"},{"key":"2903_CR148","doi-asserted-by":"publisher","first-page":"e71223","DOI":"10.1002\/cam4.71223","volume":"14","author":"L Xiong","year":"2025","unstructured":"Xiong, L. & Cheng, J. Cellular senescence and immunosenescence in melanoma: insights from the tumor microenvironment. Cancer Med 14, e71223 (2025).","journal-title":"Cancer Med"},{"key":"2903_CR149","doi-asserted-by":"publisher","first-page":"291","DOI":"10.20517\/cdr.2022.141","volume":"6","author":"S Benavente","year":"2023","unstructured":"Benavente, S. Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer. Cancer Drug Resist 6, 291\u2013313 (2023).","journal-title":"Cancer Drug Resist"},{"key":"2903_CR150","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/biom12040580","volume":"12","author":"L Zhu","year":"2022","unstructured":"Zhu, L., Zhu, X. & Wu, Y. Effects of glucose metabolism, lipid metabolism, and glutamine metabolism on tumor microenvironment and clinical implications. Biomolecules. 12, 580 (2022).","journal-title":"Biomolecules."},{"key":"2903_CR151","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1002\/mco2.789","volume":"5","author":"R Xu","year":"2024","unstructured":"Xu, R. et al. Immunometabolism: signaling pathways, homeostasis, and therapeutic targets. MedComm 5, e789 (2024).","journal-title":"MedComm"},{"key":"2903_CR152","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.it.2021.09.002","volume":"42","author":"LF Somarribas Patterson","year":"2021","unstructured":"Somarribas Patterson, L. F. & Vardhana, S. A. Metabolic regulation of the cancer-immunity cycle. Trends Immunol 42, 975\u2013993 (2021).","journal-title":"Trends Immunol"},{"key":"2903_CR153","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-023-06483-w","volume":"621","author":"M Reina-Campos","year":"2023","unstructured":"Reina-Campos, M. et al. Metabolic programs of T cell tissue residency empower tumour immunity. Nature 621, 179\u2013187 (2023).","journal-title":"Nature"},{"key":"2903_CR154","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.immuni.2016.08.017","volume":"45","author":"H Zeng","year":"2016","unstructured":"Zeng, H. et al. mTORC1 and mTORC2 kinase signaling and glucose metabolism drive follicular helper T cell differentiation. Immunity 45, 540\u2013554 (2016).","journal-title":"Immunity"},{"key":"2903_CR155","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41590-020-00848-3","volume":"22","author":"N Lopes","year":"2021","unstructured":"Lopes, N. et al. Distinct metabolic programs established in the thymus control effector functions of \u03b3\u03b4 T cell subsets in tumor microenvironments. Nat. Immunol. 22, 179\u2013192 (2021).","journal-title":"Nat. Immunol."},{"key":"2903_CR156","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41423-026-01409-8","volume":"23","author":"S Fu","year":"2026","unstructured":"Fu, S. et al. MAIT cell plasticity generates CD4(+) MAIT cells that promote HCC progression via metabolic crosstalk with tumor cells. Cell Mol. Immunol. 23, 491\u2013504 (2026).","journal-title":"Cell Mol. Immunol."},{"key":"2903_CR157","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.4049\/jimmunol.1302062","volume":"192","author":"A Caro-Maldonado","year":"2014","unstructured":"Caro-Maldonado, A. et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J. Immunol. 192, 3626\u20133636 (2014).","journal-title":"J. Immunol."},{"key":"2903_CR158","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-021-00926-0","volume":"22","author":"A Cumpelik","year":"2021","unstructured":"Cumpelik, A. et al. Dynamic regulation of B cell complement signaling is integral to germinal center responses. Nat. Immunol. 22, 757\u2013768 (2021).","journal-title":"Nat. Immunol."},{"key":"2903_CR159","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41590-025-02102-0","volume":"26","author":"E Martinis","year":"2025","unstructured":"Martinis, E. et al. B cell immunometabolism in health and disease. Nat. Immunol. 26, 366\u2013377 (2025).","journal-title":"Nat. Immunol."},{"key":"2903_CR160","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41423-021-00662-3","volume":"18","author":"SP Metur","year":"2021","unstructured":"Metur, S. P. & Klionsky, D. J. Adaptive immunity at the crossroads of autophagy and metabolism. Cell Mol. Immunol. 18, 1096\u20131105 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2903_CR161","doi-asserted-by":"publisher","first-page":"e01968","DOI":"10.1002\/advs.202501968","volume":"12","author":"Y Mao","year":"2025","unstructured":"Mao, Y. et al. Nanomedicine-driven modulation of reductive stress for cancer therapy. Adv. Sci. 12, e01968 (2025).","journal-title":"Adv. Sci."},{"key":"2903_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1626","volume":"14","author":"M Barberis","year":"2024","unstructured":"Barberis, M. & Rojas L\u00f3pez, A. Metabolic imbalance driving immune cell phenotype switching in autoimmune disorders: Tipping the balance of T- and B-cell interactions. Clin. Transl. Med. 14, e1626 (2024).","journal-title":"Clin. Transl. Med."},{"key":"2903_CR163","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.4049\/jimmunol.0802978","volume":"182","author":"R Spolski","year":"2009","unstructured":"Spolski, R. et al. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 182, 2859\u20132867 (2009).","journal-title":"J. Immunol."},{"key":"2903_CR164","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/imr.12855","volume":"295","author":"J Jellusova","year":"2020","unstructured":"Jellusova, J. The role of metabolic checkpoint regulators in B cell survival and transformation. Immunol. Rev. 295, 39\u201353 (2020).","journal-title":"Immunol. Rev."},{"key":"2903_CR165","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/imr.13377","volume":"328","author":"B Heyman","year":"2024","unstructured":"Heyman, B. Antibody feedback regulation. Immunol. Rev. 328, 126\u2013142 (2024).","journal-title":"Immunol. Rev."},{"key":"2903_CR166","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/genes14101953","volume":"14","author":"I Flati","year":"2023","unstructured":"Flati, I. et al. Molecular mechanisms underpinning immunometabolic reprogramming: how the wind changes during cancer progression. Genes 14, 1953 (2023).","journal-title":"Genes"},{"key":"2903_CR167","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.it.2025.11.002","volume":"47","author":"CY Wu","year":"2025","unstructured":"Wu, C. Y., Huang, C. X., Wei, Y. & Kuang, D. M. Glycolytic diversity drives immune complexity in cancer. Trends Immunol 47, 436\u2013448 (2025).","journal-title":"Trends Immunol"},{"key":"2903_CR168","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2025.10.005","volume":"117","author":"XX Wang","year":"2025","unstructured":"Wang, X. X., Liang, J. J., Duan, X. & Chen, G. Microbial metabolites for cancer immunotherapy: current evidence and future directions. Semin Cancer Biol 117, 89\u2013110 (2025).","journal-title":"Semin Cancer Biol"},{"key":"2903_CR169","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","volume":"597","author":"RA Kamber","year":"2021","unstructured":"Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549\u2013554 (2021).","journal-title":"Nature"},{"key":"2903_CR170","doi-asserted-by":"publisher","first-page":"109209","DOI":"10.1016\/j.celrep.2021.109209","volume":"35","author":"AY Mah-Som","year":"2021","unstructured":"Mah-Som, A. Y. et al. Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. Cell Rep 35, 109209 (2021).","journal-title":"Cell Rep"},{"key":"2903_CR171","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","volume":"33","author":"SM Poznanski","year":"2021","unstructured":"Poznanski, S. M. et al. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell Metab 33, 1205\u20131220.e1205 (2021).","journal-title":"Cell Metab"},{"key":"2903_CR172","doi-asserted-by":"publisher","first-page":"2378520","DOI":"10.1080\/2162402X.2024.2378520","volume":"13","author":"C Cantoni","year":"2024","unstructured":"Cantoni, C. et al. Human NK cells and cancer. Oncoimmunology 13, 2378520 (2024).","journal-title":"Oncoimmunology"},{"key":"2903_CR173","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone, L., Dumas, P. Y., Vienne, M. & Vivier, E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18, 671\u2013688 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR174","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.tips.2023.08.009","volume":"44","author":"S Borde","year":"2023","unstructured":"Borde, S. & Matosevic, S. Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities. Trends Pharm. Sci. 44, 832\u2013848 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"2903_CR175","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmed.2025.04.004","volume":"32","author":"T Verhezen","year":"2026","unstructured":"Verhezen, T., Wouters, A., Smits, E. & De Waele, J. Powering immunity: mitochondrial dynamics in natural killer cells. Trends Mol. Med. 32, 49\u201364 (2026).","journal-title":"Trends Mol. Med."},{"key":"2903_CR176","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/hep.32658","volume":"78","author":"X Guo","year":"2023","unstructured":"Guo, X. et al. NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology 78, 468\u2013485 (2023).","journal-title":"Hepatology"},{"key":"2903_CR177","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.3390\/ijms20174131","volume":"20","author":"J Pi\u00f1eiro Fern\u00e1ndez","year":"2019","unstructured":"Pi\u00f1eiro Fern\u00e1ndez, J., Luddy, K. A., Harmon, C. & O\u2019Farrelly, C. Hepatic tumor microenvironments and effects on NK cell phenotype and function. Int. J. Mol. Sci. 20, 4131 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR178","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563\u2013575 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR179","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1158\/0008-5472.CAN-12-3876","volume":"73","author":"J Liang","year":"2013","unstructured":"Liang, J. & Mills, G. B. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73, 2929\u20132935 (2013).","journal-title":"Cancer Res"},{"key":"2903_CR180","doi-asserted-by":"publisher","first-page":"102334","DOI":"10.1016\/j.redox.2022.102334","volume":"53","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Inhibition of nuclear deacetylase Sirtuin-1 induces mitochondrial acetylation and calcium overload leading to cell death. Redox Biol 53, 102334 (2022).","journal-title":"Redox Biol"},{"key":"2903_CR181","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci, R. et al. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 4, e1008824 (2015).","journal-title":"Oncoimmunology"},{"key":"2903_CR182","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-physiol-050824-111031","volume":"88","author":"A Grover","year":"2026","unstructured":"Grover, A., Tcyganov, E. N. & Gabrilovich, D. I. Myeloid cell reprogramming and immune suppression. Annu. Rev. Physiol. 88, 437\u2013457 (2026).","journal-title":"Annu. Rev. Physiol."},{"key":"2903_CR183","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/ijms23010135","volume":"23","author":"S Yu","year":"2021","unstructured":"Yu, S. et al. The influence of mitochondrial-DNA-driven inflammation pathways on macrophage polarization: a new perspective for targeted immunometabolic therapy in cerebral ischemia-reperfusion injury. Int. J. Mol. Sci. 23, 135 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR184","doi-asserted-by":"publisher","first-page":"1586315","DOI":"10.3389\/fimmu.2025.1586315","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targeting. Front. Immunol. 16, 1586315 (2025).","journal-title":"Front. Immunol."},{"key":"2903_CR185","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li, M. et al. Metabolism, metabolites, and macrophages in cancer. J. Hematol. Oncol. 16, 80 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2903_CR186","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin, R., Neufeld, L. & McGaha, T. L. Linking macrophage metabolism to function in the tumor microenvironment. Nat. Cancer 6, 239\u2013252 (2025).","journal-title":"Nat. Cancer"},{"key":"2903_CR187","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molmet.2019.07.006","volume":"33","author":"VL Payen","year":"2020","unstructured":"Payen, V. L. et al. Monocarboxylate transporters in cancer. Mol. Metab. 33, 48\u201366 (2020).","journal-title":"Mol. Metab."},{"key":"2903_CR188","doi-asserted-by":"publisher","first-page":"624746","DOI":"10.3389\/fimmu.2021.624746","volume":"12","author":"N Luque-Campos","year":"2021","unstructured":"Luque-Campos, N. et al. The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming. Front. Immunol. 12, 624746 (2021).","journal-title":"Front. Immunol."},{"key":"2903_CR189","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.3390\/ijms22094430","volume":"22","author":"JH Nam","year":"2021","unstructured":"Nam, J. H. et al. Functional ambivalence of dendritic cells: tolerogenicity and immunogenicity. Int. J. Mol. Sci. 22, 4430 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR190","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/ctm2.37","volume":"10","author":"KM Hargadon","year":"2020","unstructured":"Hargadon, K. M. Tumor microenvironmental influences on dendritic cell and T cell function: a focus on clinically relevant immunologic and metabolic checkpoints. Clin. Transl. Med 10, 374\u2013411 (2020).","journal-title":"Clin. Transl. Med"},{"key":"2903_CR191","doi-asserted-by":"publisher","first-page":"e008053","DOI":"10.1136\/jitc-2023-008053","volume":"12","author":"R Turpin","year":"2024","unstructured":"Turpin, R. et al. Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment. J. Immunother. Cancer. 12, e008053 (2024).","journal-title":"J. Immunother. Cancer."},{"key":"2903_CR192","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","volume":"25","author":"CY Moon","year":"2025","unstructured":"Moon, C. Y. et al. Dendritic cell maturation in cancer. Nat. Rev. Cancer 25, 225\u2013248 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR193","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.isci.2021.103067","volume":"24","author":"H Kanemaru","year":"2021","unstructured":"Kanemaru, H. et al. A mechanism of cooling hot tumors: lactate attenuates inflammation in dendritic cells. iScience 24, 103067 (2021).","journal-title":"iScience"},{"key":"2903_CR194","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E. & Gabrilovich, D. I. Functional states of myeloid cells in cancer. Cancer Cell 41, 490\u2013504 (2023).","journal-title":"Cancer Cell"},{"key":"2903_CR195","doi-asserted-by":"publisher","first-page":"100874","DOI":"10.1016\/j.jlr.2025.100874","volume":"66","author":"I Yokoseki","year":"2025","unstructured":"Yokoseki, I. et al. Chromatin remodeler BRD9 represses transcription of PPAR\u03b1 target genes, including CPT1A to suppress lipid metabolism. J. Lipid Res. 66, 100874 (2025).","journal-title":"J. Lipid Res."},{"key":"2903_CR196","doi-asserted-by":"publisher","first-page":"eadv6582","DOI":"10.1126\/science.adv6582","volume":"392","author":"Z You","year":"2026","unstructured":"You, Z. et al. Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity. Science 392, eadv6582 (2026).","journal-title":"Science"},{"key":"2903_CR197","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.cmet.2026.04.010","volume":"38","author":"I Heras-Murillo","year":"2026","unstructured":"Heras-Murillo, I. et al. Mitochondrial metabolism regulates the immunogenic responsiveness of dendritic cells. Cell Metab 38, 1254 (2026).","journal-title":"Cell Metab"},{"key":"2903_CR198","doi-asserted-by":"publisher","first-page":"e70073","DOI":"10.1111\/imr.70073","volume":"336","author":"CM Polonio","year":"2025","unstructured":"Polonio, C. M., Qualiotto, A. N., da Silva, L. T. & Quintana, F. J. Dendritic cells: orchestrators of immune responsiveness and tolerance. Immunol. Rev. 336, e70073 (2025).","journal-title":"Immunol. Rev."},{"key":"2903_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32849-1","volume":"13","author":"J Adamik","year":"2022","unstructured":"Adamik, J. et al. Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. Nat. Commun. 13, 5184 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"2903_CR201","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR202","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/0008-5472.CAN-15-0204","volume":"76","author":"AJ Giles","year":"2016","unstructured":"Giles, A. J. et al. Activation of hematopoietic stem\/progenitor cells promotes immunosuppression within the pre-metastatic niche. Cancer Res 76, 1335\u20131347 (2016).","journal-title":"Cancer Res"},{"key":"2903_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei, L. et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol. Cancer 22, 29 (2023).","journal-title":"Mol. Cancer"},{"key":"2903_CR204","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ccell.2025.11.001","volume":"44","author":"W Guo","year":"2026","unstructured":"Guo, W. et al. Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer Cell 44, 94\u2013111.e111 (2026).","journal-title":"Cancer Cell"},{"key":"2903_CR205","doi-asserted-by":"publisher","first-page":"e2503009","DOI":"10.1002\/advs.202503009","volume":"12","author":"T He","year":"2025","unstructured":"He, T. et al. CXCL6 reshapes lipid metabolism and induces neutrophil extracellular trap formation in cholangiocarcinoma progression and immunotherapy resistance. Adv. Sci. 12, e2503009 (2025).","journal-title":"Adv. Sci."},{"key":"2903_CR206","doi-asserted-by":"publisher","first-page":"e006434","DOI":"10.1136\/jitc-2022-006434","volume":"11","author":"SY Neo","year":"2023","unstructured":"Neo, S. Y. et al. Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer. J. Immunother. Cancer 11, e006434 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR207","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I. et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab 30, 36\u201350 (2019).","journal-title":"Cell Metab"},{"key":"2903_CR208","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.it.2021.12.004","volume":"43","author":"X Liu","year":"2022","unstructured":"Liu, X., Hoft, D. F. & Peng, G. Tumor microenvironment metabolites directing T cell differentiation and function. Trends Immunol 43, 132\u2013147 (2022).","journal-title":"Trends Immunol"},{"key":"2903_CR209","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","volume":"9","author":"MB Watowich","year":"2023","unstructured":"Watowich, M. B., Gilbert, M. R. & Larion, M. T cell exhaustion in malignant gliomas. Trends Cancer 9, 270\u2013292 (2023).","journal-title":"Trends Cancer"},{"key":"2903_CR210","doi-asserted-by":"publisher","first-page":"657293","DOI":"10.3389\/fimmu.2021.657293","volume":"12","author":"J Traba","year":"2021","unstructured":"Traba, J., Sack, M. N., Waldmann, T. A. & Anton, O. M. Immunometabolism at the nexus of cancer therapeutic efficacy and resistance. Front. Immunol. 12, 657293 (2021).","journal-title":"Front. Immunol."},{"key":"2903_CR211","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41423-025-01290-x","volume":"22","author":"E Manchon","year":"2025","unstructured":"Manchon, E. et al. Harnessing nutrient scarcity for enhanced CAR-T-cell potency and safety in solid tumors. Cell Mol. Immunol. 22, 645\u2013660 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2903_CR212","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41392-025-02140-y","volume":"10","author":"Y Cai","year":"2025","unstructured":"Cai, Y. et al. Phototherapy in cancer treatment: strategies and challenges. Signal Transduct. Target Ther 10, 115 (2025).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR213","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-019-0103-4","volume":"5","author":"L Du","year":"2020","unstructured":"Du, L. et al. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway. Signal Transduct. Target Ther 5, 10 (2020).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR214","doi-asserted-by":"publisher","first-page":"100941","DOI":"10.1016\/j.xcrm.2023.100941","volume":"4","author":"JCN Kenski","year":"2023","unstructured":"Kenski, J. C. N. et al. An adverse tumor-protective effect of IDO1 inhibition. Cell Rep. Med. 4, 100941 (2023).","journal-title":"Cell Rep. Med."},{"key":"2903_CR215","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cellimm.2015.09.011","volume":"299","author":"S Ostrand-Rosenberg","year":"2016","unstructured":"Ostrand-Rosenberg, S. Tolerance and immune suppression in the tumor microenvironment. Cell Immunol 299, 23\u201329 (2016).","journal-title":"Cell Immunol"},{"key":"2903_CR216","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s12672-025-03038-5","volume":"16","author":"P Bian","year":"2025","unstructured":"Bian, P. et al. Exploring PTPN6 as a dual oncogenic and immunological marker in melanoma. Discov. Oncol. 16, 1203 (2025).","journal-title":"Discov. Oncol."},{"key":"2903_CR217","doi-asserted-by":"publisher","first-page":"14928","DOI":"10.3390\/ijms241914928","volume":"24","author":"J Xing","year":"2023","unstructured":"Xing, J., Zhang, J. & Wang, J. The immune regulatory role of adenosine in the tumor microenvironment. Int. J. Mol. Sci. 24, 14928 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR218","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.immuni.2023.11.010","volume":"56","author":"YL Tsai","year":"2023","unstructured":"Tsai, Y. L. et al. TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments. Immunity 56, 2682\u20132698.e2689 (2023).","journal-title":"Immunity"},{"key":"2903_CR219","doi-asserted-by":"publisher","first-page":"598626","DOI":"10.3389\/fonc.2020.598626","volume":"10","author":"A Naik","year":"2020","unstructured":"Naik, A. & Decock, J. Lactate metabolism and immune modulation in breast cancer: a focused review on triple negative breast tumors. Front. Oncol. 10, 598626 (2020).","journal-title":"Front. Oncol."},{"key":"2903_CR220","doi-asserted-by":"publisher","first-page":"e010040","DOI":"10.1136\/jitc-2024-010040","volume":"12","author":"Q Xue","year":"2024","unstructured":"Xue, Q. et al. Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion. J. Immunother. Cancer 12, e010040 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR221","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert, B. et al. Lactate Metabolism in Human Lung Tumors. Cell 171, 358\u2013371.e359 (2017).","journal-title":"Cell"},{"key":"2903_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32521-8","volume":"13","author":"Q Feng","year":"2022","unstructured":"Feng, Q. et al. Lactate increases stemness of CD8\u2009+\u2009T cells to augment anti-tumor immunity. Nat. Commun. 13, 4981 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR223","doi-asserted-by":"publisher","first-page":"112461","DOI":"10.1016\/j.intimp.2024.112461","volume":"137","author":"Z Fan","year":"2024","unstructured":"Fan, Z. et al. Lactate drives the ESM1-SCD1 axis to inhibit the antitumor CD8(+) T-cell response by activating the Wnt\/\u03b2-catenin pathway in ovarian cancer cells and inducing cisplatin resistance. Int. Immunopharmacol. 137, 112461 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2903_CR224","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong, W. et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut 72, 2272\u20132285 (2023).","journal-title":"Gut"},{"key":"2903_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07122-6","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng, Y. et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis 15, 775 (2024).","journal-title":"Cell Death Dis"},{"key":"2903_CR226","doi-asserted-by":"publisher","first-page":"e2105376","DOI":"10.1002\/advs.202105376","volume":"9","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. Biomimetic nanocarriers guide extracellular ATP homeostasis to remodel energy metabolism for activating innate and adaptive immunity system. Adv. Sci. 9, e2105376 (2022).","journal-title":"Adv. Sci."},{"key":"2903_CR227","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/biomedicines12092146","volume":"12","author":"RI Mihaila","year":"2024","unstructured":"Mihaila, R. I., Gheorghe, A. S., Zob, D. L. & Stanculeanu, D. L. The importance of predictive biomarkers and their correlation with the response to immunotherapy in solid tumors-impact on clinical practice. Biomedicines 12, 2146 (2024).","journal-title":"Biomedicines"},{"key":"2903_CR228","first-page":"512","volume":"22","author":"B Zhu","year":"2024","unstructured":"Zhu, B. et al. The signature of extracellular vesicles in hypoxic breast cancer and their therapeutic engineering. Cell Commun. Signal 22, 512 (2024).","journal-title":"Signal"},{"key":"2903_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03450-z","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu, D. et al. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2\/PLK1\/PTEN pathway. Cell Death Dis 12, 162 (2021).","journal-title":"Cell Death Dis"},{"key":"2903_CR230","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02216-w","volume":"23","author":"M Tian","year":"2025","unstructured":"Tian, M. et al. Glycosylation as an intricate post-translational modification process takes part in glycoproteins related immunity. Cell Commun. Signal 23, 214 (2025).","journal-title":"Cell Commun. Signal"},{"key":"2903_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).","journal-title":"Mol. Cancer"},{"key":"2903_CR232","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-016-0106-5","volume":"5","author":"V Ribas","year":"2016","unstructured":"Ribas, V., Garc\u00eda-Ruiz, C. & Fern\u00e1ndez-Checa, J. C. Mitochondria, cholesterol and cancer cell metabolism. Clin. Transl. Med. 5, 22 (2016).","journal-title":"Clin. Transl. Med."},{"key":"2903_CR233","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.3390\/ijms25063313","volume":"25","author":"AG Magar","year":"2024","unstructured":"Magar, A. G. et al. A Molecular perspective on hif-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update. Int. J. Mol. Sci. 25, 3313 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR234","doi-asserted-by":"publisher","first-page":"978276","DOI":"10.3389\/fonc.2022.978276","volume":"12","author":"W Cheng","year":"2022","unstructured":"Cheng, W. et al. Conducive target range of breast cancer: Hypoxic tumor microenvironment. Front. Oncol. 12, 978276 (2022).","journal-title":"Front. Oncol."},{"key":"2903_CR235","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00262-021-03126-9","volume":"71","author":"E Cluff","year":"2022","unstructured":"Cluff, E. et al. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K\/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells. Cancer Immunol. Immunother. 71, 1989\u20132005 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"2903_CR236","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12672-024-01117-7","volume":"15","author":"L Chuang","year":"2024","unstructured":"Chuang, L., Qifeng, J. & Shaolei, Y. The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer. Discov. Oncol. 15, 244 (2024).","journal-title":"Discov. Oncol."},{"key":"2903_CR237","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","volume":"27","author":"CA Lyssiotis","year":"2017","unstructured":"Lyssiotis, C. A. & Kimmelman, A. C. Metabolic interactions in the tumor microenvironment. Trends Cell Biol 27, 863\u2013875 (2017).","journal-title":"Trends Cell Biol"},{"key":"2903_CR238","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351\u2013359 (2015).","journal-title":"Nat. Cell Biol."},{"key":"2903_CR239","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.abb2683","volume":"371","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science 371, 405\u2013410 (2021).","journal-title":"Science"},{"key":"2903_CR240","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2903_CR241","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"2903_CR242","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41590-024-01985-9","volume":"25","author":"D Raychaudhuri","year":"2024","unstructured":"Raychaudhuri, D. et al. Histone lactylation drives CD8(+) T cell metabolism and function. Nat. Immunol. 25, 2140\u20132151 (2024).","journal-title":"Nat. Immunol."},{"key":"2903_CR243","doi-asserted-by":"publisher","first-page":"e012230","DOI":"10.1136\/jitc-2025-012230","volume":"13","author":"S Liu","year":"2025","unstructured":"Liu, S. et al. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J. Immunother. Cancer 13, e012230 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR244","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-024-02943-x","volume":"43","author":"Q Meng","year":"2024","unstructured":"Meng, Q. et al. Lactylation stabilizes DCBLD1 activating the pentose phosphate pathway to promote cervical cancer progression. J. Exp. Clin. Cancer Res. 43, 36 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2903_CR245","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.drup.2025.101248","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun, Y. et al. Lactylation in cancer progression and drug resistance. Drug Resist. Updat. 81, 101248 (2025).","journal-title":"Drug Resist. Updat."},{"key":"2903_CR246","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2024.10.015","volume":"37","author":"R Zhu","year":"2025","unstructured":"Zhu, R. et al. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab 37, 361\u2013376.e367 (2025).","journal-title":"Cell Metab"},{"key":"2903_CR247","doi-asserted-by":"publisher","first-page":"110911","DOI":"10.1016\/j.isci.2024.110911","volume":"27","author":"R Du","year":"2024","unstructured":"Du, R. et al. Sirtuin 1\/sirtuin 3 are robust lysine delactylases and sirtuin 1-mediated delactylation regulates glycolysis. iScience 27, 110911 (2024).","journal-title":"iScience"},{"key":"2903_CR248","doi-asserted-by":"publisher","first-page":"217901","DOI":"10.1016\/j.canlet.2025.217901","volume":"630","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. PD-L1 delactylation-promoted nuclear translocation accelerates liver cancer growth through elevating SQLE transcription activity. Cancer Lett 630, 217901 (2025).","journal-title":"Cancer Lett"},{"key":"2903_CR249","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1093\/nar\/gkae183","volume":"52","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Dux activates metabolism-lactylation-MET network during early iPSC reprogramming with Brg1 as the histone lactylation reader. Nucleic Acids Res 52, 5529\u20135548 (2024).","journal-title":"Nucleic Acids Res"},{"key":"2903_CR250","doi-asserted-by":"publisher","first-page":"e2421496121","DOI":"10.1073\/pnas.2421496121","volume":"121","author":"G Zhai","year":"2024","unstructured":"Zhai, G. et al. DPF2 reads histone lactylation to drive transcription and tumorigenesis. Proc. Natl. Acad. Sci. USA 121, e2421496121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2903_CR251","doi-asserted-by":"publisher","first-page":"1620723","DOI":"10.3389\/fgene.2025.1620723","volume":"16","author":"X Zhou","year":"2025","unstructured":"Zhou, X. et al. Aerobic exercise-induced lactate production: a novel opportunity for remodeling the tumor microenvironment. Front. Genet. 16, 1620723 (2025).","journal-title":"Front. Genet."},{"key":"2903_CR252","doi-asserted-by":"publisher","first-page":"e70226","DOI":"10.1002\/mco2.70226","volume":"6","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Lactylation: from homeostasis to pathological implications and therapeutic strategies. MedComm 6, e70226 (2025).","journal-title":"MedComm"},{"key":"2903_CR253","doi-asserted-by":"publisher","first-page":"105502","DOI":"10.1016\/j.ebiom.2024.105502","volume":"111","author":"C Bao","year":"2025","unstructured":"Bao, C. et al. Histone lactylation in macrophage biology and disease: from plasticity regulation to therapeutic implications. EBioMedicine 111, 105502 (2025).","journal-title":"EBioMedicine"},{"key":"2903_CR254","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","volume":"42","author":"T Sun","year":"2023","unstructured":"Sun, T. et al. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. J. Exp. Clin. Cancer Res. 42, 253 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2903_CR255","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40880-018-0302-3","volume":"38","author":"YP Wang","year":"2018","unstructured":"Wang, Y. P. & Lei, Q. Y. Metabolic recoding of epigenetics in cancer. Cancer Commun. 38, 25 (2018).","journal-title":"Cancer Commun."},{"key":"2903_CR256","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-cancerbio-070820-035832","volume":"5","author":"LT Izzo","year":"2021","unstructured":"Izzo, L. T., Affronti, H. C. & Wellen, K. E. The bidirectional relationship between cancer epigenetics and metabolism. Annu. Rev. Cancer Biol. 5, 235\u2013257 (2021).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"2903_CR257","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.3390\/ijms25084265","volume":"25","author":"S Zheng","year":"2024","unstructured":"Zheng, S. et al. Neutrophil elastase degrades histone deacetylases and sirtuin 1 in primary human monocyte derived macrophages. Int. J. Mol. Sci. 25, 4265 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR258","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat. Cell Biol. 22, 1064\u20131075 (2020).","journal-title":"Nat. Cell Biol."},{"key":"2903_CR259","doi-asserted-by":"publisher","first-page":"17422","DOI":"10.3390\/ijms242417422","volume":"24","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. The role of tumor metabolic reprogramming in tumor immunity. Int. J. Mol. Sci. 24, 17422 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR260","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00018-023-05104-z","volume":"81","author":"H Shi","year":"2024","unstructured":"Shi, H. et al. A glimpse into novel acylations and their emerging role in regulating cancer metastasis. Cell Mol. Life Sci 81, 76 (2024).","journal-title":"Cell Mol. Life Sci"},{"key":"2903_CR261","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","volume":"57","author":"L Liang","year":"2025","unstructured":"Liang, L. et al. Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat. Genet 57, 680\u2013693 (2025).","journal-title":"Nat. Genet"},{"key":"2903_CR262","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-023-06061-0","volume":"617","author":"H Yuan","year":"2023","unstructured":"Yuan, H. et al. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature 617, 818\u2013826 (2023).","journal-title":"Nature"},{"key":"2903_CR263","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-025-00627-6","volume":"14","author":"Q Hu","year":"2025","unstructured":"Hu, Q. et al. Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy. Exp. Hematol. Oncol. 14, 37 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2903_CR264","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58524-9","volume":"16","author":"JJ Chi","year":"2025","unstructured":"Chi, J. J. et al. MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer. Nat. Commun. 16, 3552 (2025).","journal-title":"Nat. Commun."},{"key":"2903_CR265","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40164-025-00693-w","volume":"14","author":"X Ren","year":"2025","unstructured":"Ren, X. et al. Bisecting GlcNAc enhances CD8(+) T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1. Exp. Hematol. Oncol. 14, 102 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"2903_CR266","doi-asserted-by":"publisher","first-page":"e2216796120","DOI":"10.1073\/pnas.2216796120","volume":"120","author":"Q Zhu","year":"2023","unstructured":"Zhu, Q. et al. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation. Proc. Natl. Acad. Sci. USA 120, e2216796120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2903_CR267","doi-asserted-by":"publisher","first-page":"105677","DOI":"10.1016\/j.jbc.2024.105677","volume":"300","author":"J Zhang","year":"2024","unstructured":"Zhang, J. & Wang, Y. Emerging roles of O-GlcNAcylation in protein trafficking and secretion. J. Biol. Chem. 300, 105677 (2024).","journal-title":"J. Biol. Chem."},{"key":"2903_CR268","doi-asserted-by":"publisher","first-page":"e15127","DOI":"10.1002\/advs.202515127","volume":"13","author":"H Mei","year":"2026","unstructured":"Mei, H. et al. Targeting DESI2 as a novel therapeutic strategy for JAK2-mutant leukemias. Adv. Sci. 13, e15127 (2026).","journal-title":"Adv. Sci."},{"key":"2903_CR269","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao, H. et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3, 306\u2013317 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"2903_CR270","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10555-019-09787-4","volume":"38","author":"A Ibrahim-Hashim","year":"2019","unstructured":"Ibrahim-Hashim, A. & Estrella, V. Acidosis and cancer: from mechanism to neutralization. Cancer Metastasis Rev 38, 149\u2013155 (2019).","journal-title":"Cancer Metastasis Rev"},{"key":"2903_CR271","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41392-022-01151-3","volume":"7","author":"X Li","year":"2022","unstructured":"Li, X. et al. Lactate metabolism in human health and disease. Signal Transduct. Target Ther 7, 305 (2022).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR272","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-10-2828","volume":"71","author":"F V\u00e9gran","year":"2011","unstructured":"V\u00e9gran, F. et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-\u03baB\/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71, 2550\u20132560 (2011).","journal-title":"Cancer Res"},{"key":"2903_CR273","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cell.2020.11.043","volume":"184","author":"N Wang","year":"2021","unstructured":"Wang, N. et al. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates. Cell 184, 370\u2013383.e313 (2021).","journal-title":"Cell"},{"key":"2903_CR274","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00018-018-2784-1","volume":"75","author":"Y Nonnenmacher","year":"2018","unstructured":"Nonnenmacher, Y. & Hiller, K. Biochemistry of proinflammatory macrophage activation. Cell Mol. Life Sci 75, 2093\u20132109 (2018).","journal-title":"Cell Mol. Life Sci"},{"key":"2903_CR275","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","volume":"77","author":"JY Wu","year":"2020","unstructured":"Wu, J. Y. et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol. Cell 77, 213\u2013227.e215 (2020).","journal-title":"Mol. Cell"},{"key":"2903_CR276","doi-asserted-by":"publisher","first-page":"e177824","DOI":"10.1172\/JCI177824","volume":"135","author":"KE Kay","year":"2024","unstructured":"Kay, K. E. et al. Tumor cell-derived spermidine promotes a protumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition. J. Clin. Investig. 135, e177824 (2024).","journal-title":"J. Clin. Investig."},{"key":"2903_CR277","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.cell.2025.11.034","volume":"189","author":"J Gu","year":"2026","unstructured":"Gu, J. et al. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. Cell 189, 418\u2013434.e424 (2026).","journal-title":"Cell"},{"key":"2903_CR278","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo, G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. Science 377, 1519\u20131529 (2022).","journal-title":"Science"},{"key":"2903_CR279","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41556-025-01673-2","volume":"27","author":"J Wan","year":"2025","unstructured":"Wan, J. et al. Lactate dehydrogenase B facilitates disulfidptosis and exhaustion of tumour-infiltrating CD8(+) T cells. Nat. Cell Biol. 27, 972\u2013982 (2025).","journal-title":"Nat. Cell Biol."},{"key":"2903_CR280","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","volume":"18","author":"N Dumauthioz","year":"2021","unstructured":"Dumauthioz, N. et al. Enforced PGC-1\u03b1 expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol. Immunol. 18, 1761\u20131771 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2903_CR281","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1126\/science.abq1053","volume":"381","author":"KC Mangalhara","year":"2023","unstructured":"Mangalhara, K. C. et al. Manipulating mitochondrial electron flow enhances tumor immunogenicity. Science 381, 1316\u20131323 (2023).","journal-title":"Science"},{"key":"2903_CR282","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3390\/biomedicines10123120","volume":"10","author":"A Santarsiero","year":"2022","unstructured":"Santarsiero, A. et al. Mitochondrial role in intrinsic apoptosis induced by a new synthesized chalcone in hepatocellular carcinoma cells. Biomedicines 10, 3120 (2022).","journal-title":"Biomedicines"},{"key":"2903_CR283","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41422-020-0301-1","volume":"30","author":"J Saravia","year":"2020","unstructured":"Saravia, J. et al. Signaling networks in immunometabolism. Cell Res 30, 328\u2013342 (2020).","journal-title":"Cell Res"},{"key":"2903_CR284","doi-asserted-by":"publisher","first-page":"107115","DOI":"10.1016\/j.phrs.2024.107115","volume":"202","author":"Y Hai","year":"2024","unstructured":"Hai, Y. et al. A novel mitochondria-targeting DHODH inhibitor induces robust ferroptosis and alleviates immune suppression. Pharm. Res. 202, 107115 (2024).","journal-title":"Pharm. Res."},{"key":"2903_CR285","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46377-7","volume":"15","author":"L Simula","year":"2024","unstructured":"Simula, L. et al. Mitochondrial metabolism sustains CD8(+) T cell migration for an efficient infiltration into solid tumors. Nat. Commun. 15, 2203 (2024).","journal-title":"Nat. Commun."},{"key":"2903_CR286","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cmet.2025.03.003","volume":"37","author":"SS Mortazavi Farsani","year":"2025","unstructured":"Mortazavi Farsani, S. S. et al. Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy. Cell Metab 37, 1294\u20131310.e1297 (2025).","journal-title":"Cell Metab"},{"key":"2903_CR287","doi-asserted-by":"publisher","first-page":"14667","DOI":"10.1021\/acsnano.3c02428","volume":"17","author":"J Yan","year":"2023","unstructured":"Yan, J. et al. Metal-phenolic nanomedicines regulate T-cell antitumor function for sono-metabolic cancer therapy. ACS Nano 17, 14667\u201314677 (2023).","journal-title":"ACS Nano"},{"key":"2903_CR288","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"L Wu","year":"2023","unstructured":"Wu, L. et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab 35, 1580\u20131596.e1589 (2023).","journal-title":"Cell Metab"},{"key":"2903_CR289","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02302-0","volume":"24","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK\/mTOR pathway. Mol. Cancer 24, 97 (2025).","journal-title":"Mol. Cancer"},{"key":"2903_CR290","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41577-024-01098-2","volume":"25","author":"S Can\u00e8","year":"2025","unstructured":"Can\u00e8, S., Geiger, R. & Bronte, V. The roles of arginases and arginine in immunity. Nat. Rev. Immunol. 25, 266\u2013284 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"2903_CR291","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12459","volume":"43","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun 43, 909\u2013937 (2023).","journal-title":"Cancer Commun"},{"key":"2903_CR292","doi-asserted-by":"publisher","first-page":"31846","DOI":"10.1021\/acsnano.4c08083","volume":"18","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Nutritional glutamine-modified iron-delivery system with enhanced endocytosis for ferroptosis therapy of pancreatic tumors. ACS Nano 18, 31846\u201331868 (2024).","journal-title":"ACS Nano"},{"key":"2903_CR293","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2022.12.003","volume":"56","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Ji, L. & Li, M. O. Control of tumor-associated macrophage responses by nutrient acquisition and metabolism. Immunity 56, 14\u201331 (2023).","journal-title":"Immunity"},{"key":"2903_CR294","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ccell.2023.04.016","volume":"41","author":"C Yan","year":"2023","unstructured":"Yan, C. et al. Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. Cancer Cell 41, 1276\u20131293.e1211 (2023).","journal-title":"Cancer Cell"},{"key":"2903_CR295","doi-asserted-by":"publisher","first-page":"eaaz6314","DOI":"10.1126\/scitranslmed.aaz6314","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy. Sci. Transl. Med. 13, eaaz6314 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2903_CR296","doi-asserted-by":"publisher","first-page":"eado3485","DOI":"10.1126\/sciimmunol.ado3485","volume":"10","author":"J Liang","year":"2025","unstructured":"Liang, J. et al. Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma. Sci. Immunol. 10, eado3485 (2025).","journal-title":"Sci. Immunol."},{"key":"2903_CR297","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/1078-0432.CCR-14-3279","volume":"21","author":"AJ Leiker","year":"2015","unstructured":"Leiker, A. J. et al. Radiation enhancement of head and neck squamous cell carcinoma by the dual PI3K\/mTOR inhibitor PF-05212384. Clin. Cancer Res 21, 2792\u20132801 (2015).","journal-title":"Clin. Cancer Res"},{"key":"2903_CR298","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jhep.2024.05.007","volume":"81","author":"CX Zhu","year":"2024","unstructured":"Zhu, C. X. et al. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma. J. Hepatol. 81, 690\u2013703 (2024).","journal-title":"J. Hepatol."},{"key":"2903_CR299","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/HEP.0000000000000704","volume":"81","author":"C Yin","year":"2025","unstructured":"Yin, C. et al. ALDOB\/KAT2A interactions epigenetically modulate TGF-\u03b2 expression and T cell functions in hepatocellular carcinogenesis. Hepatology 81, 77\u201393 (2025).","journal-title":"Hepatology"},{"key":"2903_CR300","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s42255-022-00543-7","volume":"4","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. MAPK signalling-induced phosphorylation and subcellular translocation of PDHE1\u03b1 promotes tumour immune evasion. Nat. Metab. 4, 374\u2013388 (2022).","journal-title":"Nat. Metab."},{"key":"2903_CR301","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","volume":"17","author":"S Scalera","year":"2022","unstructured":"Scalera, S. et al. KEAP1-mutant NSCLC: the catastrophic failure of a cell-protecting hub. J. Thorac. Oncol. 17, 751\u2013757 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2903_CR302","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.immuni.2025.05.006","volume":"58","author":"ZY Liu","year":"2025","unstructured":"Liu, Z. Y. et al. Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity 58, 1572\u20131585.e1510 (2025).","journal-title":"Immunity"},{"key":"2903_CR303","doi-asserted-by":"publisher","first-page":"947188","DOI":"10.3389\/fonc.2022.947188","volume":"12","author":"M Di Modica","year":"2022","unstructured":"Di Modica, M. et al. The link between the microbiota and HER2+ breast cancer: the new challenge of precision medicine. Front. Oncol. 12, 947188 (2022).","journal-title":"Front. Oncol."},{"key":"2903_CR304","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41586-023-06749-3","volume":"623","author":"H Fan","year":"2023","unstructured":"Fan, H. et al. Trans-vaccenic acid reprograms CD8(+) T cells and anti-tumour immunity. Nature 623, 1034\u20131043 (2023).","journal-title":"Nature"},{"key":"2903_CR305","doi-asserted-by":"publisher","first-page":"e2411086","DOI":"10.1002\/advs.202411086","volume":"12","author":"B Chen","year":"2025","unstructured":"Chen, B. et al. Gut microbiota-butyrate-PPAR\u03b3 axis modulates adipose regulatory T cell population. Adv. Sci 12, e2411086 (2025).","journal-title":"Adv. Sci"},{"key":"2903_CR306","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.immuni.2025.10.004","volume":"58","author":"A Bachem","year":"2025","unstructured":"Bachem, A. et al. Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8(+) T cell immunity against melanoma. Immunity 58, 2799\u20132813.e2798 (2025).","journal-title":"Immunity"},{"key":"2903_CR307","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","volume":"33","author":"Y He","year":"2021","unstructured":"He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab 33, 988\u20131000.e1007 (2021).","journal-title":"Cell Metab"},{"key":"2903_CR308","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-023-01734-4","volume":"12","author":"JH Xing","year":"2024","unstructured":"Xing, J. H. et al. Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets. Microbiome 12, 20 (2024).","journal-title":"Microbiome"},{"key":"2903_CR309","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.24537","volume":"54","author":"A Baghdasaryan","year":"2011","unstructured":"Baghdasaryan, A. et al. Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO\u207b\u2083 output. Hepatology 54, 1303\u20131312 (2011).","journal-title":"Hepatology"},{"key":"2903_CR310","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.cmet.2025.01.011","volume":"37","author":"H Wei","year":"2025","unstructured":"Wei, H. et al. AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. Cell Metab 37, 1103\u20131118.e1107 (2025).","journal-title":"Cell Metab"},{"key":"2903_CR311","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","journal-title":"Science"},{"key":"2903_CR312","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1016\/j.cell.2025.06.018","volume":"188","author":"CM Phelps","year":"2025","unstructured":"Phelps, C. M. et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell 188, 5680\u20135700.e5628 (2025).","journal-title":"Cell"},{"key":"2903_CR313","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.adh7954","volume":"384","author":"E Giampazolias","year":"2024","unstructured":"Giampazolias, E. et al. Vitamin D regulates microbiome-dependent cancer immunity. Science 384, 428\u2013437 (2024).","journal-title":"Science"},{"key":"2903_CR314","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17644-0","volume":"11","author":"A Buqu\u00e9","year":"2020","unstructured":"Buqu\u00e9, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).","journal-title":"Nat. Commun."},{"key":"2903_CR315","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","volume":"615","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168\u2013174 (2023).","journal-title":"Nature"},{"key":"2903_CR316","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846\u20131862.e1826 (2023).","journal-title":"Cell"},{"key":"2903_CR317","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"},{"key":"2903_CR318","doi-asserted-by":"publisher","first-page":"eabn0704","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 7, eabn0704 (2022).","journal-title":"Sci. Immunol."},{"key":"2903_CR319","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211\u2013218 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"2903_CR320","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","volume":"34","author":"D Guo","year":"2022","unstructured":"Guo, D. et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1. Cell Metab 34, 1312\u20131324.e1316 (2022).","journal-title":"Cell Metab"},{"key":"2903_CR321","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cac2.12158","volume":"41","author":"JZ Wang","year":"2021","unstructured":"Wang, J. Z. et al. The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun 41, 560\u2013575 (2021).","journal-title":"Cancer Commun"},{"key":"2903_CR322","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41586-023-06409-6","volume":"620","author":"LM Sanmarco","year":"2023","unstructured":"Sanmarco, L. M. et al. Lactate limits CNS autoimmunity by stabilizing HIF-1\u03b1 in dendritic cells. Nature 620, 881\u2013889 (2023).","journal-title":"Nature"},{"key":"2903_CR323","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57099-9","volume":"16","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nat. Commun. 16, 1762 (2025).","journal-title":"Nat. Commun."},{"key":"2903_CR324","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity 54, 1561\u20131577.e1567 (2021).","journal-title":"Immunity"},{"key":"2903_CR325","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298\u2013308 (2020).","journal-title":"Nat. Immunol."},{"key":"2903_CR326","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie, B. W., Bao, R. & Luke, J. J. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin. Cancer Res. 25, 1462\u20131471 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR327","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/s41556-024-01503-x","volume":"26","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Ammonia-induced lysosomal and mitochondrial damage causes cell death of effector CD8(+) T cells. Nat. Cell Biol. 26, 1892\u20131902 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2903_CR328","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.cmet.2025.03.004","volume":"37","author":"EM P\u00e5lsson-McDermott","year":"2025","unstructured":"P\u00e5lsson-McDermott, E. M. & O\u2019Neill, L. A. J. Gang of 3: How the Krebs cycle-linked metabolites itaconate, succinate, and fumarate regulate macrophages and inflammation. Cell Metab 37, 1049\u20131059 (2025).","journal-title":"Cell Metab"},{"key":"2903_CR329","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07312-2","volume":"16","author":"L Pedrera","year":"2025","unstructured":"Pedrera, L. et al. Ferroptosis triggers mitochondrial fragmentation via Drp1 activation. Cell Death Dis 16, 40 (2025).","journal-title":"Cell Death Dis"},{"key":"2903_CR330","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05264-1","volume":"610","author":"F Baixauli","year":"2022","unstructured":"Baixauli, F. et al. An LKB1-mitochondria axis controls T(H)17 effector function. Nature 610, 555\u2013561 (2022).","journal-title":"Nature"},{"key":"2903_CR331","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.immuni.2025.03.005","volume":"58","author":"P Lai","year":"2025","unstructured":"Lai, P. et al. Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. Immunity 58, 811\u2013825.e817 (2025).","journal-title":"Immunity"},{"key":"2903_CR332","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54352-5","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Proteomic profiling of gliomas unveils immune and metabolism-driven subtypes with implications for anti-nucleotide metabolism therapy. Nat. Commun. 15, 10005 (2024).","journal-title":"Nat. Commun."},{"key":"2903_CR333","doi-asserted-by":"publisher","first-page":"115327","DOI":"10.1016\/j.celrep.2025.115327","volume":"44","author":"Q Zhang","year":"2025","unstructured":"Zhang, Q. et al. Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancer. Cell Rep 44, 115327 (2025).","journal-title":"Cell Rep"},{"key":"2903_CR334","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-024-08224-z","volume":"636","author":"YJ Chen","year":"2024","unstructured":"Chen, Y. J. et al. Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. Nature 636, 466\u2013473 (2024).","journal-title":"Nature"},{"key":"2903_CR335","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.tem.2024.05.010","volume":"35","author":"Y Qiu","year":"2024","unstructured":"Qiu, Y. et al. One-carbon metabolism shapes T cell immunity in cancer. Trends Endocrinol. Metab. 35, 967\u2013980 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"2903_CR336","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.immuni.2023.07.002","volume":"56","author":"KM Luda","year":"2023","unstructured":"Luda, K. M. et al. Ketolysis drives CD8(+) T cell effector function through effects on histone acetylation. Immunity 56, 2021\u20132035.e2028 (2023).","journal-title":"Immunity"},{"key":"2903_CR337","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","volume":"57","author":"L Zitvogel","year":"2024","unstructured":"Zitvogel, L., Fidelle, M. & Kroemer, G. Long-distance microbial mechanisms impacting cancer immunosurveillance. Immunity 57, 2013\u20132029 (2024).","journal-title":"Immunity"},{"key":"2903_CR338","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s44222-023-00039-3","volume":"1","author":"MR Blatchley","year":"2023","unstructured":"Blatchley, M. R. & Anseth, K. S. Middle-out methods for spatiotemporal tissue engineering of organoids. Nat. Rev. Bioeng. 1, 329\u2013345 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"2903_CR339","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-19-1228","volume":"10","author":"B Ngo","year":"2020","unstructured":"Ngo, B. et al. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov 10, 1352\u20131373 (2020).","journal-title":"Cancer Discov"},{"key":"2903_CR340","doi-asserted-by":"publisher","first-page":"366","DOI":"10.21147\/j.issn.1000-9604.2019.02.11","volume":"31","author":"X Ma","year":"2019","unstructured":"Ma, X. et al. Histogram analysis of apparent diffusion coefficient predicts response to radiofrequency ablation in hepatocellular carcinoma. Chin. J. Cancer Res. 31, 366\u2013374 (2019).","journal-title":"Chin. J. Cancer Res."},{"key":"2903_CR341","doi-asserted-by":"publisher","first-page":"7840606","DOI":"10.1155\/2022\/7840606","volume":"2022","author":"D Xie","year":"2022","unstructured":"Xie, D. et al. Circulating metabolic markers related to the diagnosis of hepatocellular carcinoma. J. Oncol. 2022, 7840606 (2022).","journal-title":"J. Oncol."},{"key":"2903_CR342","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06606-z","volume":"23","author":"B Park","year":"2025","unstructured":"Park, B. et al. Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment. J. Transl. Med 23, 633 (2025).","journal-title":"J. Transl. Med"},{"key":"2903_CR343","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10555-025-10251-9","volume":"44","author":"TH Chen","year":"2025","unstructured":"Chen, T. H. et al. Mitochondrial alterations and signatures in hepatocellular carcinoma. Cancer Metastasis Rev 44, 34 (2025).","journal-title":"Cancer Metastasis Rev"},{"key":"2903_CR344","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2147\/JHC.S510460","volume":"12","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. A novel prognostic signature integrating immune and glycolytic pathways for enhanced prognosis and immunotherapy prediction in hepatocellular carcinoma. J. Hepatocell. Carcinoma 12, 805\u2013823 (2025).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"2903_CR345","doi-asserted-by":"publisher","first-page":"20573","DOI":"10.1002\/cam4.6623","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancer. Cancer Med 12, 20573\u201320589 (2023).","journal-title":"Cancer Med"},{"key":"2903_CR346","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07482-7","volume":"16","author":"CH Ding","year":"2025","unstructured":"Ding, C. H. et al. PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. Cell Death Dis 16, 158 (2025).","journal-title":"Cell Death Dis"},{"key":"2903_CR347","doi-asserted-by":"publisher","first-page":"1608115","DOI":"10.3389\/fimmu.2025.1608115","volume":"16","author":"X Che","year":"2025","unstructured":"Che, X. et al. The lactylation-macrophage interplay: implications for gastrointestinal disease therapeutics. Front Immunol 16, 1608115 (2025).","journal-title":"Front Immunol"},{"key":"2903_CR348","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12672-026-04485-4","volume":"17","author":"X Pan","year":"2026","unstructured":"Pan, X., Ye, T., Liu, J. & Zheng, X. Integrated analysis of glutamine metabolism and immune microenvironment identifies GOT2 as a prognostic gene in head and neck squamous cell carcinoma. Discov. Oncol. 17, 446 (2026).","journal-title":"Discov. Oncol."},{"key":"2903_CR349","doi-asserted-by":"publisher","first-page":"27811","DOI":"10.1073\/pnas.2007770117","volume":"117","author":"MO Bernabeu","year":"2020","unstructured":"Bernabeu, M. O. et al. Abnormal morphology biases hematocrit distribution in tumor vasculature and contributes to heterogeneity in tissue oxygenation. Proc. Natl. Acad. Sci. USA 117, 27811\u201327819 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2903_CR350","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato, P. E. et al. Mitochondrial metabolism and cancer. Cell Res 28, 265\u2013280 (2018).","journal-title":"Cell Res"},{"key":"2903_CR351","first-page":"116","volume":"21","author":"C Jiang","year":"2023","unstructured":"Jiang, C. et al. Small extracellular vesicle-mediated metabolic reprogramming: from tumors to pre-metastatic niche formation. Cell Commun. Signal 21, 116 (2023).","journal-title":"Signal"},{"key":"2903_CR352","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05356-w","volume":"13","author":"F Stuhldreier","year":"2022","unstructured":"Stuhldreier, F. et al. The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism. Cell Death Dis 13, 938 (2022).","journal-title":"Cell Death Dis"},{"key":"2903_CR353","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cas.14246","volume":"111","author":"T Huang","year":"2020","unstructured":"Huang, T. et al. Lactate-fueled oxidative metabolism drives DNA methyltransferase 1-mediated transcriptional co-activator with PDZ binding domain protein activation. Cancer Sci 111, 186\u2013199 (2020).","journal-title":"Cancer Sci"},{"key":"2903_CR354","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-020-01724-6","volume":"39","author":"F Mudassar","year":"2020","unstructured":"Mudassar, F., Shen, H., O\u2019Neill, G. & Hau, E. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J. Exp. Clin. Cancer Res. 39, 208 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2903_CR355","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","volume":"33","author":"MJ Borad","year":"2015","unstructured":"Borad, M. J. et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 33, 1475\u20131481 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR356","doi-asserted-by":"publisher","first-page":"1184869","DOI":"10.3389\/fmicb.2023.1184869","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Gut Streptococcus is a microbial marker for the occurrence and liver metastasis of pancreatic cancer. Front Microbiol 14, 1184869 (2023).","journal-title":"Front Microbiol"},{"key":"2903_CR357","doi-asserted-by":"publisher","first-page":"e0299421","DOI":"10.1128\/mBio.02994-21","volume":"12","author":"D Yu","year":"2021","unstructured":"Yu, D. et al. Fecal streptococcus alteration is associated with gastric cancer occurrence and liver metastasis. mBio 12, e0299421 (2021).","journal-title":"mBio"},{"key":"2903_CR358","doi-asserted-by":"publisher","first-page":"e70037","DOI":"10.1002\/cam4.70037","volume":"13","author":"D Yu","year":"2024","unstructured":"Yu, D. et al. Gut Roseburia is a protective marker for peritoneal metastasis of gastric cancer. Cancer Med 13, e70037 (2024).","journal-title":"Cancer Med"},{"key":"2903_CR359","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jcmgh.2017.10.007","volume":"5","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Formation of human colonic crypt array by application of chemical gradients across a shaped epithelial monolayer. Cell Mol. Gastroenterol. Hepatol. 5, 113\u2013130 (2018).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2903_CR360","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1880241","volume":"13","author":"JS Lee","year":"2021","unstructured":"Lee, J. S., Wang, R. X., Alexeev, E. E. & Colgan, S. P. Intestinal inflammation as a dysbiosis of energy procurement: new insights into an old topic. Gut Microbes 13, 1\u201320 (2021).","journal-title":"Gut Microbes"},{"key":"2903_CR361","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3390\/ijms19071939","volume":"19","author":"PC Lin","year":"2018","unstructured":"Lin, P. C., Hsieh, H. Y., Chu, P. C. & Chen, C. S. Therapeutic opportunities of targeting histone deacetylase isoforms to eradicate cancer stem cells. Int. J. Mol. Sci. 19, 1939 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR362","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/biomedicines13061357","volume":"13","author":"BF Theis","year":"2025","unstructured":"Theis, B. F. et al. Gut Feelings: how microbes, diet, and host immunity shape disease. Biomedicines 13, 1357 (2025).","journal-title":"Biomedicines"},{"key":"2903_CR363","first-page":"326","volume":"67","author":"AP Bhatt","year":"2017","unstructured":"Bhatt, A. P., Redinbo, M. R. & Bultman, S. J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin 67, 326\u2013344 (2017).","journal-title":"CA Cancer J. Clin"},{"key":"2903_CR364","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45636-x","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Dubosiella newyorkensis modulates immune tolerance in colitis via the L-lysine-activated AhR-IDO1-Kyn pathway. Nat. Commun. 15, 1333 (2024).","journal-title":"Nat. Commun."},{"key":"2903_CR365","doi-asserted-by":"publisher","first-page":"e13606","DOI":"10.1002\/advs.202513606","volume":"13","author":"Z Wang","year":"2026","unstructured":"Wang, Z. et al. IL4I1\u207a macrophages and TDO2\u207a myofibroblasts drive AhR-mediated immunosuppression and ferroptosis resistance in solid predominant lung adenocarcinoma. Adv. Sci. 13, e13606 (2026).","journal-title":"Adv. Sci."},{"key":"2903_CR366","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12859-025-06110-7","volume":"26","author":"Q Weng","year":"2025","unstructured":"Weng, Q., Hu, M., Peng, G. & Zhu, J. DMoVGPE: predicting gut microbial associated metabolites profiles with deep mixture of variational Gaussian Process experts. BMC Bioinform 26, 93 (2025).","journal-title":"BMC Bioinform"},{"key":"2903_CR367","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut 72, 2112\u20132122 (2023).","journal-title":"Gut"},{"key":"2903_CR368","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong, L., Li, N. & Zhang, Z. Emerging therapies for glioblastoma: current state and future directions. J. Exp. Clin. Cancer Res. 41, 142 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2903_CR369","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/biom10101370","volume":"10","author":"F Martins","year":"2020","unstructured":"Martins, F., Gon\u00e7alves, L. G., Pojo, M. & Serpa, J. Take advantage of glutamine anaplerosis, the kernel of the metabolic rewiring in malignant gliomas. Biomolecules. 10, 1370 (2020).","journal-title":"Biomolecules."},{"key":"2903_CR370","doi-asserted-by":"publisher","first-page":"175909141881826","DOI":"10.1177\/1759091418818261","volume":"10","author":"C Chinopoulos","year":"2018","unstructured":"Chinopoulos, C. & Seyfried, T. N. Mitochondrial substrate-level phosphorylation as energy source for glioblastoma: review and hypothesis. ASN Neuro 10, 1759091418818261 (2018).","journal-title":"ASN Neuro"},{"key":"2903_CR371","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/md22090391","volume":"22","author":"DN Liu","year":"2024","unstructured":"Liu, D. N. et al. Chrysomycin A reshapes metabolism and increases oxidative stress to hinder glioblastoma progression. Mar Drugs 22, 391 (2024).","journal-title":"Mar Drugs"},{"key":"2903_CR372","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajpath.2025.04.013","volume":"195","author":"LH Westerlund","year":"2025","unstructured":"Westerlund, L. H., Bergstr\u00f6m, C. K., Laakkonen, P. M. & Le Joncour, V. Deciphering the dialogue between brain tumors, neurons, and astrocytes. Am. J. Pathol. 195, 1193\u20131208 (2025).","journal-title":"Am. J. Pathol."},{"key":"2903_CR373","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4103\/mgr.MEDGASRES-D-24-00147","volume":"15","author":"L Zhao","year":"2025","unstructured":"Zhao, L., Lee, Z. H. & Shah, Y. M. Ammonia as a critical metabolic modulator of anti-tumor immunity. Med. Gas. Res. 15, 446\u2013447 (2025).","journal-title":"Med. Gas. Res."},{"key":"2903_CR374","doi-asserted-by":"publisher","first-page":"e2305989","DOI":"10.1002\/advs.202305989","volume":"11","author":"W Li","year":"2024","unstructured":"Li, W. et al. Boosting microglial lipid metabolism via TREM2 Signaling by biomimetic nanoparticles to attenuate the sevoflurane-induced developmental neurotoxicity. Adv. Sci. 11, e2305989 (2024).","journal-title":"Adv. Sci."},{"key":"2903_CR375","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00018-025-05648-2","volume":"82","author":"A Montilla","year":"2025","unstructured":"Montilla, A. et al. Microglia regulate myelin clearance and cholesterol metabolism after demyelination via interferon regulatory factor 5. Cell Mol. Life Sci 82, 131 (2025).","journal-title":"Cell Mol. Life Sci"},{"key":"2903_CR376","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02011-0","volume":"21","author":"Y Qi","year":"2023","unstructured":"Qi, Y. et al. New trends in brain tumor immunity with the opportunities of lymph nodes targeted drug delivery. J. Nanobiotechnology 21, 254 (2023).","journal-title":"J. Nanobiotechnology"},{"key":"2903_CR377","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35, 428\u2013440.e425 (2019).","journal-title":"Cancer Cell"},{"key":"2903_CR378","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.gendis.2025.101521","volume":"12","author":"X Wu","year":"2025","unstructured":"Wu, X. et al. Landscape of metabolic alterations and treatment strategies in breast cancer. Genes Dis 12, 101521 (2025).","journal-title":"Genes Dis"},{"key":"2903_CR379","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-019-0778-6","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. Cancer-associated adipocytes: key players in breast cancer progression. J. Hematol. Oncol. 12, 95 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2903_CR380","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie, E. et al. Cellular fatty acid metabolism and cancer. Cell Metab 18, 153\u2013161 (2013).","journal-title":"Cell Metab"},{"key":"2903_CR381","doi-asserted-by":"publisher","first-page":"14556","DOI":"10.1002\/cam4.5984","volume":"12","author":"M Sohel","year":"2023","unstructured":"Sohel, M. et al. Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: a comprehensive review. Cancer Med 12, 14556\u201314583 (2023).","journal-title":"Cancer Med"},{"key":"2903_CR382","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 389, 2430\u20132442 (2017).","journal-title":"Lancet"},{"key":"2903_CR383","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 31, 178\u2013186 (2021).","journal-title":"Cell Res"},{"key":"2903_CR384","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res 32, 477\u2013490 (2022).","journal-title":"Cell Res"},{"key":"2903_CR385","doi-asserted-by":"publisher","first-page":"1105117","DOI":"10.3389\/fonc.2023.1105117","volume":"13","author":"C Yan","year":"2023","unstructured":"Yan, C. et al. FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation. Front. Oncol. 13, 1105117 (2023).","journal-title":"Front. Oncol."},{"key":"2903_CR386","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.molmed.2020.03.004","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J., Sauter, E. R. & Li, B. FABP4: a new player in obesity-associated breast cancer. Trends Mol. Med. 26, 437\u2013440 (2020).","journal-title":"Trends Mol. Med."},{"key":"2903_CR387","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tcb.2025.04.007","volume":"35","author":"R Thakur","year":"2025","unstructured":"Thakur, R., Mullen, N. J., Mehla, K. & Singh, P. K. Tumor-stromal metabolic crosstalk in pancreatic cancer. Trends Cell Biol 35, 1068\u20131083 (2025).","journal-title":"Trends Cell Biol"},{"key":"2903_CR388","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ccell.2021.02.016","volume":"39","author":"H Su","year":"2021","unstructured":"Su, H. et al. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell 39, 678\u2013693.e611 (2021).","journal-title":"Cancer Cell"},{"key":"2903_CR389","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-19-0959","volume":"10","author":"SJ Parker","year":"2020","unstructured":"Parker, S. J. et al. Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer. Cancer Discov 10, 1018\u20131037 (2020).","journal-title":"Cancer Discov"},{"key":"2903_CR390","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05891-2","volume":"616","author":"MS Lee","year":"2023","unstructured":"Lee, M. S. et al. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Nature 616, 339\u2013347 (2023).","journal-title":"Nature"},{"key":"2903_CR391","first-page":"1315","volume":"19","author":"H Xu","year":"2022","unstructured":"Xu, H. et al. Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy. Cancer Biol. Med. 19, 1315\u20131333 (2022).","journal-title":"Cancer Biol. Med."},{"key":"2903_CR392","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-14","volume":"5","author":"KK Singh","year":"2006","unstructured":"Singh, K. K., Desouki, M. M., Franklin, R. B. & Costello, L. C. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol. Cancer 5, 14 (2006).","journal-title":"Mol. Cancer"},{"key":"2903_CR393","first-page":"143","volume":"4","author":"P Chetta","year":"2021","unstructured":"Chetta, P. & Zadra, G. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer. Cancer Drug Resist 4, 143\u2013162 (2021).","journal-title":"Cancer Drug Resist"},{"key":"2903_CR394","doi-asserted-by":"publisher","first-page":"116296","DOI":"10.1016\/j.bone.2021.116296","volume":"168","author":"D Gr\u010devi\u0107","year":"2023","unstructured":"Gr\u010devi\u0107, D., Sanjay, A. & Lorenzo, J. Interactions of B-lymphocytes and bone cells in health and disease. Bone 168, 116296 (2023).","journal-title":"Bone"},{"key":"2903_CR395","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.cell.2021.03.011","volume":"184","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 184, 2471\u20132486.e2420 (2021).","journal-title":"Cell"},{"key":"2903_CR396","doi-asserted-by":"publisher","first-page":"9609","DOI":"10.2147\/JIR.S529149","volume":"18","author":"X Shang","year":"2025","unstructured":"Shang, X. Mechanosensitive miRNAs in cartilage and subchondral bone remodeling: emerging targets for osteoarthritis therapy. J. Inflamm. Res. 18, 9609\u20139625 (2025).","journal-title":"J. Inflamm. Res."},{"key":"2903_CR397","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41590-023-01738-0","volume":"25","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. Lithium carbonate revitalizes tumor-reactive CD8(+) T cells by shunting lactic acid into mitochondria. Nat. Immunol. 25, 552\u2013561 (2024).","journal-title":"Nat. Immunol."},{"key":"2903_CR398","doi-asserted-by":"publisher","first-page":"675385","DOI":"10.3389\/fendo.2021.675385","volume":"12","author":"W Da","year":"2021","unstructured":"Da, W., Tao, L. & Zhu, Y. The role of osteoclast energy metabolism in the occurrence and development of osteoporosis. Front Endocrinol 12, 675385 (2021).","journal-title":"Front Endocrinol"},{"key":"2903_CR399","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3389\/fonc.2020.01012","volume":"10","author":"F La Manna","year":"2020","unstructured":"La Manna, F. et al. Dual-mTOR inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. Front. Oncol. 10, 1012 (2020).","journal-title":"Front. Oncol."},{"key":"2903_CR400","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1002\/mco2.676","volume":"5","author":"A Jiang","year":"2024","unstructured":"Jiang, A. et al. Renal cancer: signaling pathways and advances in targeted therapies. MedComm 5, e676 (2024).","journal-title":"MedComm"},{"key":"2903_CR401","doi-asserted-by":"publisher","first-page":"e93411","DOI":"10.1172\/jci.insight.93411","volume":"2","author":"PJ Siska","year":"2017","unstructured":"Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2, e93411 (2017).","journal-title":"JCI Insight"},{"key":"2903_CR402","doi-asserted-by":"publisher","first-page":"103734","DOI":"10.1016\/j.ebiom.2021.103734","volume":"74","author":"PJ Siska","year":"2021","unstructured":"Siska, P. J. et al. Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo. EBioMedicine 74, 103734 (2021).","journal-title":"EBioMedicine"},{"key":"2903_CR403","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35036-4","volume":"13","author":"M Sciacovelli","year":"2022","unstructured":"Sciacovelli, M. et al. Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression. Nat. Commun. 13, 7830 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR404","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.trecan.2023.02.005","volume":"9","author":"K Ganguly","year":"2023","unstructured":"Ganguly, K. & Kimmelman, A. C. Reprogramming of tissue metabolism during cancer metastasis. Trends Cancer 9, 461\u2013471 (2023).","journal-title":"Trends Cancer"},{"key":"2903_CR405","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/ijms24021768","volume":"24","author":"H Salaun","year":"2023","unstructured":"Salaun, H. et al. Total Polyunsaturated Fatty Acid Level in Abdominal Adipose Tissue as an Independent Predictor of Recurrence-Free Survival in Women with Ovarian Cancer. Int. J. Mol. Sci. 24, 1768 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR406","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01708-4","volume":"22","author":"L Zeng","year":"2023","unstructured":"Zeng, L. et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol. Cancer 22, 10 (2023).","journal-title":"Mol. Cancer"},{"key":"2903_CR407","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41573-024-01098-w","volume":"24","author":"S Viel","year":"2025","unstructured":"Viel, S., Vivier, E., Walzer, T. & Mar\u00e7ais, A. Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer. Nat. Rev. Drug Discov. 24, 190\u2013208 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2903_CR408","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41573-025-01227-z","volume":"24","author":"MP Trefny","year":"2025","unstructured":"Trefny, M. P., Kroemer, G. & Zitvogel, L. & Kobold, S. Metabolites as agents and targets for cancer immunotherapy. Nat. Rev. Drug Discov. 24, 764\u2013784 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2903_CR409","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.7150\/ijbs.86039","volume":"19","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. The emerging roles of metabolism in the crosstalk between breast cancer cells and tumor-associated macrophages. Int J. Biol. Sci. 19, 4915\u20134930 (2023).","journal-title":"Int J. Biol. Sci."},{"key":"2903_CR410","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41586-023-06482-x","volume":"621","author":"MR Mamedov","year":"2023","unstructured":"Mamedov, M. R. et al. CRISPR screens decode cancer cell pathways that trigger \u03b3\u03b4 T cell detection. Nature 621, 188\u2013195 (2023).","journal-title":"Nature"},{"key":"2903_CR411","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell, T. C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II Trial (ECHO-202\/KEYNOTE-037). J. Clin. Oncol. 36, 3223\u20133230 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR412","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20, 1083\u20131097 (2019).","journal-title":"Lancet Oncol"},{"key":"2903_CR413","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cac2.12608","volume":"44","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Tryptophan 2,3-dioxygenase-positive matrix fibroblasts fuel breast cancer lung metastasis via kynurenine-mediated ferroptosis resistance of metastatic cells and T cell dysfunction. Cancer Commun 44, 1261\u20131286 (2024).","journal-title":"Cancer Commun"},{"key":"2903_CR414","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun, S. J. et al. Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nat. Commun. 15, 6640 (2024).","journal-title":"Nat. Commun."},{"key":"2903_CR415","doi-asserted-by":"publisher","first-page":"e148225","DOI":"10.1172\/JCI148225","volume":"131","author":"PJ Siska","year":"2021","unstructured":"Siska, P. J. et al. Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. J. Clin. Investig. 131, e148225 (2021).","journal-title":"J. Clin. Investig."},{"key":"2903_CR416","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda, M. A. et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10, 104536 (2025).","journal-title":"ESMO Open"},{"key":"2903_CR417","doi-asserted-by":"publisher","first-page":"e2409875","DOI":"10.1002\/smll.202409875","volume":"21","author":"JE Cun","year":"2025","unstructured":"Cun, J. E. et al. Copper-based bio-coordination nanoparticle for enhanced pyroptosis-cuproptosis cancer immunotherapy through redox modulation and glycolysis inhibition. Small 21, e2409875 (2025).","journal-title":"Small"},{"key":"2903_CR418","doi-asserted-by":"publisher","first-page":"eabq3016","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng, J. J. et al. Metabolic challenges and interventions in CAR T cell therapy. Sci. Immunol. 8, eabq3016 (2023).","journal-title":"Sci. Immunol."},{"key":"2903_CR419","doi-asserted-by":"publisher","first-page":"e006522","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos, K. et al. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J. Immunother. Cancer 11, e006522 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR420","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/ijc.30646","volume":"140","author":"J P\u00f6tzl","year":"2017","unstructured":"P\u00f6tzl, J. et al. Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-\u03b3 and induces NK cell-dependent lymphoma control without other immunotherapies. Int. J. Cancer 140, 2125\u20132133 (2017).","journal-title":"Int. J. Cancer"},{"key":"2903_CR421","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell, M. D. et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase i first-in-humans study of (89)Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J. Nucl. Med. 63, 720\u2013726 (2022).","journal-title":"J. Nucl. Med."},{"key":"2903_CR422","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12350-017-1131-5","volume":"25","author":"O Manabe","year":"2018","unstructured":"Manabe, O. et al. Radiopharmaceutical tracers for cardiac imaging. J. Nucl. Cardiol. 25, 1204\u20131236 (2018).","journal-title":"J. Nucl. Cardiol."},{"key":"2903_CR423","doi-asserted-by":"publisher","first-page":"15831","DOI":"10.3390\/ijms232415831","volume":"23","author":"YF Yang","year":"2022","unstructured":"Yang, Y. F. et al. Application of metabolic reprogramming to cancer imaging and diagnosis. Int. J. Mol. Sci. 23, 15831 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2903_CR424","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.eururo.2013.08.053","volume":"65","author":"R Schiavina","year":"2014","unstructured":"Schiavina, R., Brunocilla, E. & Martorana, G. The new promise of FACBC position emission tomography\/computed tomography in the localization of disease relapse after radical treatment for prostate cancer: are we turning to the right radiotracer? Eur. Urol. 65, 255\u2013256 (2014).","journal-title":"Eur. Urol."},{"key":"2903_CR425","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/S2589-7500(23)00203-0","volume":"6","author":"I H\u00e4ggstr\u00f6m","year":"2024","unstructured":"H\u00e4ggstr\u00f6m, I. et al. Deep learning for [(18)F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis. Lancet Digit. Health 6, e114\u2013e125 (2024).","journal-title":"Lancet Digit. Health"},{"key":"2903_CR426","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1002\/cai2.159","volume":"4","author":"K Feng","year":"2025","unstructured":"Feng, K., Yi, Z. & Xu, B. Artificial intelligence and breast cancer management: from data to the clinic. Cancer Innov 4, e159 (2025).","journal-title":"Cancer Innov"},{"key":"2903_CR427","doi-asserted-by":"publisher","first-page":"217574","DOI":"10.1016\/j.canlet.2025.217574","volume":"616","author":"Z Zeng","year":"2025","unstructured":"Zeng, Z., Yi, Z. & Xu, B. The biological and technical challenges facing utilizing circulating tumor DNA in non-metastatic breast cancer patients. Cancer Lett 616, 217574 (2025).","journal-title":"Cancer Lett"},{"key":"2903_CR428","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-024-02047-0","volume":"9","author":"Z Yi","year":"2024","unstructured":"Yi, Z. et al. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct. Target Ther 9, 345 (2024).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR429","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41392-021-00662-9","volume":"6","author":"Z Yi","year":"2021","unstructured":"Yi, Z. et al. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct. Target Ther 6, 251 (2021).","journal-title":"Signal Transduct. Target Ther"},{"key":"2903_CR430","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm.4415","volume":"23","author":"X Jin","year":"2017","unstructured":"Jin, X. et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat. Med. 23, 1352\u20131361 (2017).","journal-title":"Nat. Med."},{"key":"2903_CR431","first-page":"vdae027","volume":"6","author":"JJ Jones","year":"2024","unstructured":"Jones, J. J. et al. Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma. Neurooncol. Adv. 6, vdae027 (2024).","journal-title":"Neurooncol. Adv."},{"key":"2903_CR432","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","volume":"11","author":"EJ Moding","year":"2021","unstructured":"Moding, E. J., Nabet, B. Y., Alizadeh, A. A. & Diehn, M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov 11, 2968\u20132986 (2021).","journal-title":"Cancer Discov"},{"key":"2903_CR433","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/cac2.12619","volume":"44","author":"F He","year":"2024","unstructured":"He, F. et al. Targeting the LMP1-ALIX axis in EBV(+) nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity. Cancer Commun 44, 1391\u20131413 (2024).","journal-title":"Cancer Commun"},{"key":"2903_CR434","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arg\u00fcello","year":"2020","unstructured":"Arg\u00fcello, R. J. et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab 32, 1063\u20131075.e1067 (2020).","journal-title":"Cell Metab"},{"key":"2903_CR435","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1002\/cai2.124","volume":"3","author":"K Feng","year":"2024","unstructured":"Feng, K. et al. A lactate-responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple-negative breast cancer. Cancer Innov 3, e124 (2024).","journal-title":"Cancer Innov"},{"key":"2903_CR436","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","volume":"30","author":"J Klughammer","year":"2024","unstructured":"Klughammer, J. et al. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat. Med. 30, 3236\u20133249 (2024).","journal-title":"Nat. Med."},{"key":"2903_CR437","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41587-023-01937-y","volume":"42","author":"M Vicari","year":"2024","unstructured":"Vicari, M. et al. Spatial multimodal analysis of transcriptomes and metabolomes in tissues. Nat. Biotechnol. 42, 1046\u20131050 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2903_CR438","doi-asserted-by":"crossref","unstructured":"Song, R. et al. ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy. Protein Cell, pwaf111 (2025).","DOI":"10.1093\/procel\/pwaf111"},{"key":"2903_CR439","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ccell.2024.07.005","volume":"42","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. Cancer Cell 42, 1386\u20131400.e1388 (2024).","journal-title":"Cancer Cell"},{"key":"2903_CR440","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096.e3019 (2025).","journal-title":"Cell"},{"key":"2903_CR441","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259\u2013268 (2023).","journal-title":"Nature"},{"key":"2903_CR442","doi-asserted-by":"publisher","first-page":"2522322","DOI":"10.1080\/07853890.2025.2522322","volume":"57","author":"W Li","year":"2025","unstructured":"Li, W. et al. Peripheral immune and inflammatory markers as predictors of neoadjuvant immunotherapy response in head and neck squamous cell carcinoma. Ann. Med. 57, 2522322 (2025).","journal-title":"Ann. Med."},{"key":"2903_CR443","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/s41591-025-04093-9","volume":"31","author":"BV Landon","year":"2025","unstructured":"Landon, B. V. et al. Liquid biopsies across the cancer care continuum. Nat. Med. 31, 4006\u20134021 (2025).","journal-title":"Nat. Med."},{"key":"2903_CR444","doi-asserted-by":"publisher","first-page":"e009140","DOI":"10.1136\/jitc-2024-009140","volume":"13","author":"K Bernatowicz","year":"2025","unstructured":"Bernatowicz, K. et al. Radiomics signature for dynamic monitoring of tumour-inflamed microenvironment and immunotherapy response prediction. J. Immunother. Cancer 13, e009140 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR445","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-25-2117","volume":"32","author":"H Jeong","year":"2026","unstructured":"Jeong, H. et al. Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: a multicenter phase II study (BRISK; KCSG AL22-16). Clin. Cancer Res 32, 291\u2013299 (2026).","journal-title":"Clin. Cancer Res"},{"key":"2903_CR446","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1158\/1078-0432.CCR-25-2367","volume":"32","author":"Y Yang","year":"2026","unstructured":"Yang, Y. et al. PET\/CT-guided neoadjuvant tislelizumab plus chemotherapy\/chemoradiotherapy for resectable esophageal squamous cell carcinoma: RATIONALE-213 final analysis. Clin. Cancer Res. 32, 1995\u20132006 (2026).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR447","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","volume":"42","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell 42, 1598\u20131613.e1594 (2024).","journal-title":"Cancer Cell"},{"key":"2903_CR448","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2025.12.017","volume":"44","author":"H Jun","year":"2026","unstructured":"Jun, H. et al. A context-augmented large language model for accurate precision oncology medicine recommendations. Cancer Cell 44, 676\u2013685.e674 (2026).","journal-title":"Cancer Cell"},{"key":"2903_CR449","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","volume":"57","author":"R Ding","year":"2024","unstructured":"Ding, R. et al. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity 57, 528\u2013540.e526 (2024).","journal-title":"Immunity"},{"key":"2903_CR450","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.molcel.2021.03.037","volume":"81","author":"X Dai","year":"2021","unstructured":"Dai, X. et al. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol. Cell 81, 2317\u20132331.e2316 (2021).","journal-title":"Mol. Cell"},{"key":"2903_CR451","doi-asserted-by":"publisher","first-page":"e2302878120","DOI":"10.1073\/pnas.2302878120","volume":"120","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc. Natl. Acad. Sci. USA 120, e2302878120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2903_CR452","doi-asserted-by":"publisher","first-page":"TPS2606","DOI":"10.1200\/jco.2015.33.15_suppl.tps2606","volume":"33","author":"RA Redman","year":"2015","unstructured":"Redman, R. A. et al. A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis. J. Clin. Oncol. 33, TPS2606 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR453","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford, S. et al. A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clin. Cancer Res 29, 1429\u20131439 (2023).","journal-title":"Clin. Cancer Res"},{"key":"2903_CR454","doi-asserted-by":"publisher","first-page":"e007349","DOI":"10.1136\/jitc-2023-007349","volume":"11","author":"N Babl","year":"2023","unstructured":"Babl, N. et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. J. Immunother. Cancer 11, e007349 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2903_CR455","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ejps.2012.08.012","volume":"47","author":"F Farabegoli","year":"2012","unstructured":"Farabegoli, F. et al. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharm. Sci. 47, 729\u2013738 (2012).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2903_CR456","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03225-9","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen, D. et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat. Commun. 9, 873 (2018).","journal-title":"Nat. Commun."},{"key":"2903_CR457","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3389\/fimmu.2017.00637","volume":"8","author":"Q Zhao","year":"2017","unstructured":"Zhao, Q. et al. 2-Deoxy-d-glucose treatment decreases anti-inflammatory M2 macrophage polarization in mice with tumor and allergic airway inflammation. Front Immunol 8, 637 (2017).","journal-title":"Front Immunol"},{"key":"2903_CR458","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341\u20131358.e1311 (2023).","journal-title":"Immunity"},{"key":"2903_CR459","doi-asserted-by":"publisher","first-page":"1896643","DOI":"10.1080\/2162402X.2021.1896643","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Combination of EP(4) antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology 10, 1896643 (2021).","journal-title":"Oncoimmunology"},{"key":"2903_CR460","doi-asserted-by":"publisher","first-page":"101234","DOI":"10.1016\/j.xcrm.2023.101234","volume":"4","author":"R Tang","year":"2023","unstructured":"Tang, R. et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Rep. Med. 4, 101234 (2023).","journal-title":"Cell Rep. Med."},{"key":"2903_CR461","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang, N. et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat. Commun. 13, 1511 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR462","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3389\/fimmu.2018.02927","volume":"9","author":"L Jiang","year":"2018","unstructured":"Jiang, L. et al. Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumour immunity by disrupting tumour-infiltrating dendritic cells. Front. Immunol. 9, 2927 (2018).","journal-title":"Front. Immunol."},{"key":"2903_CR463","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","volume":"29","author":"W Kelly","year":"2023","unstructured":"Kelly, W. et al. Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin. Cancer Res. 29, 2419\u20132425 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR464","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14728222.2017.1381087","volume":"21","author":"JA Menendez","year":"2017","unstructured":"Menendez, J. A. & Lupu, R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin. Ther. Targets 21, 1001\u20131016 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2903_CR465","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1158\/0008-5472.CAN-15-2613","volume":"76","author":"OF Kuzu","year":"2016","unstructured":"Kuzu, O. F., Noory, M. A. & Robertson, G. P. The role of cholesterol in cancer. Cancer Res 76, 2063\u20132070 (2016).","journal-title":"Cancer Res"},{"key":"2903_CR466","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.27246","volume":"9","author":"H Jin","year":"2019","unstructured":"Jin, H. et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin \u03b23\/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics 9, 265\u2013278 (2019).","journal-title":"Theranostics"},{"key":"2903_CR467","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbalip.2010.06.006","volume":"1801","author":"MG Balvers","year":"2010","unstructured":"Balvers, M. G. et al. Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties. Biochim. Biophys. Acta 1801, 1107\u20131114 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"2903_CR468","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero, J. L. et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543, 428\u2013432 (2017).","journal-title":"Nature"},{"key":"2903_CR469","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bjh.12359","volume":"162","author":"GJ Ossenkoppele","year":"2013","unstructured":"Ossenkoppele, G. J. et al. A phase I first-in-human study with tefinostat - a monocyte\/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Br. J. Haematol. 162, 191\u2013201 (2013).","journal-title":"Br. J. Haematol."},{"key":"2903_CR470","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/neuonc\/noad174","volume":"26","author":"TS Johnson","year":"2024","unstructured":"Johnson, T. S. et al. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol 26, 348\u2013361 (2024).","journal-title":"Neuro Oncol"},{"key":"2903_CR471","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1200\/JCO.2017.35.15_suppl.3066","volume":"35","author":"GG Jha","year":"2017","unstructured":"Jha, G. G. et al. A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 35, 3066 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR472","doi-asserted-by":"publisher","first-page":"e140100","DOI":"10.1172\/JCI140100","volume":"131","author":"DN Edwards","year":"2021","unstructured":"Edwards, D. N. et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J. Clin. Investig. 131, e140100 (2021).","journal-title":"J. Clin. Investig."},{"key":"2903_CR473","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molcel.2020.10.015","volume":"80","author":"JK Byun","year":"2020","unstructured":"Byun, J. K. et al. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol. Cell 80, 592\u2013606.e598 (2020).","journal-title":"Mol. Cell"},{"key":"2903_CR474","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale, I. et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ 30, 1097\u20131154 (2023).","journal-title":"Cell Death Differ"},{"key":"2903_CR475","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","volume":"28","author":"CH Lee","year":"2022","unstructured":"Lee, C. H. et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial. Clin. Cancer Res. 28, 3248\u20133255 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR476","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clin. Cancer Res. 28, 1540\u20131548 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR477","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","volume":"8","author":"NM Tannir","year":"2022","unstructured":"Tannir, N. M. et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial. JAMA Oncol 8, 1411\u20131418 (2022).","journal-title":"JAMA Oncol"},{"key":"2903_CR478","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34064-4","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. Nat. Commun. 13, 6308 (2022).","journal-title":"Nat. Commun."},{"key":"2903_CR479","doi-asserted-by":"publisher","first-page":"eabj5070","DOI":"10.1126\/scitranslmed.abj5070","volume":"13","author":"AW Chung","year":"2021","unstructured":"Chung, A. W. et al. A phase 1\/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci. Transl. Med. 13, eabj5070 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2903_CR480","doi-asserted-by":"publisher","first-page":"e11210","DOI":"10.15252\/emmm.201911210","volume":"12","author":"A Menga","year":"2020","unstructured":"Menga, A. et al. Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. EMBO Mol. Med. 12, e11210 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2903_CR481","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.celrep.2017.07.054","volume":"20","author":"EM Palmieri","year":"2017","unstructured":"Palmieri, E. M. et al. Pharmacologic or genetic targeting of glutamine synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis. Cell Rep 20, 1654\u20131666 (2017).","journal-title":"Cell Rep"},{"key":"2903_CR482","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos, P. et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386, 1519\u20131531 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2903_CR483","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2903_CR484","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov"},{"key":"2903_CR485","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR486","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","volume":"28","author":"AA Chiappori","year":"2022","unstructured":"Chiappori, A. A. et al. Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 28, 2313\u20132320 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR487","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim, E. A. et al. Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin. Cancer Res. 28, 4871\u20134884 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2903_CR488","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Investig. 127, 929\u2013941 (2017).","journal-title":"J. Clin. Investig."},{"key":"2903_CR489","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis, P. A. et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 3, 506\u2013517 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2903_CR490","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","volume":"74","author":"D Mittal","year":"2014","unstructured":"Mittal, D. et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 74, 3652\u20133658 (2014).","journal-title":"Cancer Res"},{"key":"2903_CR491","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1200\/JCO.2024.42.16_suppl.3508","volume":"42","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg, Z. A. et al. ARC-9: a randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). J. Clin. Oncol. 42, 3508 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2903_CR492","doi-asserted-by":"publisher","first-page":"eadg3736","DOI":"10.1126\/sciadv.adg3736","volume":"9","author":"OS Sarkar","year":"2023","unstructured":"Sarkar, O. S. et al. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. Sci. Adv. 9, eadg3736 (2023).","journal-title":"Sci. Adv."},{"key":"2903_CR493","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2019.12.018","volume":"147","author":"B Griess","year":"2020","unstructured":"Griess, B., Mir, S., Datta, K. & Teoh-Fitzgerald, M. Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression. Free Radic. Biol. Med. 147, 48\u201360 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"2903_CR494","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1038\/onc.2015.51","volume":"34","author":"SJ Salpeter","year":"2015","unstructured":"Salpeter, S. J. et al. A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression. Oncogene 34, 6066\u20136078 (2015).","journal-title":"Oncogene"},{"key":"2903_CR495","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2025.43.16_suppl.9511","volume":"43","author":"Y Qiu","year":"2025","unstructured":"Qiu, Y. et al. Clinical outcomes of the DIET study: a randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB). J. Clin. Oncol. 43, 9511\u20139511 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02903-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02903-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02903-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:01:56Z","timestamp":1791500516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02903-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":495,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2903"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02903-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors acknowledge the use of ChatGPT and DeepSeek for language polishing, grammar correction, and readability improvement. These tools did not influence the authors\u2019 interpretation of the literature or the scientific conclusions, and all final decisions and revisions were made by the authors.","order":2,"name":"Ethics","label":"AI statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"439"}}